JPH08511018A - 新規ペプチド誘導体 - Google Patents
新規ペプチド誘導体Info
- Publication number
- JPH08511018A JPH08511018A JP7501665A JP50166595A JPH08511018A JP H08511018 A JPH08511018 A JP H08511018A JP 7501665 A JP7501665 A JP 7501665A JP 50166595 A JP50166595 A JP 50166595A JP H08511018 A JPH08511018 A JP H08511018A
- Authority
- JP
- Japan
- Prior art keywords
- pab
- cha
- pro
- group
- hooc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 32
- 150000001875 compounds Chemical class 0.000 claims abstract description 313
- 239000012634 fragment Substances 0.000 claims abstract description 47
- 229940122388 Thrombin inhibitor Drugs 0.000 claims abstract description 27
- 239000003868 thrombin inhibitor Substances 0.000 claims abstract description 27
- 239000003112 inhibitor Substances 0.000 claims abstract description 26
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 21
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 20
- 239000003146 anticoagulant agent Substances 0.000 claims abstract description 16
- 101000712605 Theromyzon tessulatum Theromin Proteins 0.000 claims abstract description 10
- 239000004480 active ingredient Substances 0.000 claims abstract description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 4
- 229940121363 anti-inflammatory agent Drugs 0.000 claims abstract 3
- 239000002260 anti-inflammatory agent Substances 0.000 claims abstract 3
- 239000000203 mixture Substances 0.000 claims description 239
- 125000000217 alkyl group Chemical group 0.000 claims description 175
- 125000004432 carbon atom Chemical group C* 0.000 claims description 164
- 239000007858 starting material Substances 0.000 claims description 91
- 238000000034 method Methods 0.000 claims description 88
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 75
- -1 3-pyrrolidyl Chemical group 0.000 claims description 62
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 44
- 150000003839 salts Chemical class 0.000 claims description 40
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 36
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 34
- 125000006239 protecting group Chemical group 0.000 claims description 33
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims description 32
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 32
- 229910052757 nitrogen Inorganic materials 0.000 claims description 32
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 29
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims description 26
- 238000006243 chemical reaction Methods 0.000 claims description 24
- 238000010511 deprotection reaction Methods 0.000 claims description 24
- 229910052799 carbon Inorganic materials 0.000 claims description 19
- 108090000190 Thrombin Proteins 0.000 claims description 18
- 150000001413 amino acids Chemical class 0.000 claims description 18
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 claims description 18
- 229910052720 vanadium Inorganic materials 0.000 claims description 18
- 229960004072 thrombin Drugs 0.000 claims description 17
- 125000001153 fluoro group Chemical group F* 0.000 claims description 16
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 16
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 15
- 229910052731 fluorine Inorganic materials 0.000 claims description 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 12
- 239000003001 serine protease inhibitor Substances 0.000 claims description 12
- 239000000126 substance Substances 0.000 claims description 12
- 229910052721 tungsten Inorganic materials 0.000 claims description 12
- 229910052739 hydrogen Inorganic materials 0.000 claims description 11
- 108010016626 Dipeptides Proteins 0.000 claims description 10
- 230000029936 alkylation Effects 0.000 claims description 10
- 238000005804 alkylation reaction Methods 0.000 claims description 10
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 10
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims description 9
- 230000005764 inhibitory process Effects 0.000 claims description 9
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 9
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 claims description 8
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 claims description 8
- 241001465754 Metazoa Species 0.000 claims description 8
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 8
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 claims description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 8
- 125000004043 oxo group Chemical group O=* 0.000 claims description 8
- NNBZCPXTIHJBJL-MGCOHNPYSA-N trans-decalin Chemical group C1CCC[C@@H]2CCCC[C@H]21 NNBZCPXTIHJBJL-MGCOHNPYSA-N 0.000 claims description 8
- 229940122055 Serine protease inhibitor Drugs 0.000 claims description 7
- 101710102218 Serine protease inhibitor Proteins 0.000 claims description 7
- 125000004429 atom Chemical group 0.000 claims description 7
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 6
- 125000003277 amino group Chemical group 0.000 claims description 6
- 238000010561 standard procedure Methods 0.000 claims description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 5
- 241000282412 Homo Species 0.000 claims description 5
- 230000021615 conjugation Effects 0.000 claims description 5
- 238000009472 formulation Methods 0.000 claims description 5
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 229910006069 SO3H Inorganic materials 0.000 claims description 4
- 229960004676 antithrombotic agent Drugs 0.000 claims description 4
- 239000003153 chemical reaction reagent Substances 0.000 claims description 4
- 125000005842 heteroatom Chemical group 0.000 claims description 4
- 125000001424 substituent group Chemical group 0.000 claims description 4
- VVGPECAOVDZTLZ-UHFFFAOYSA-N [N]NC(N)=N Chemical compound [N]NC(N)=N VVGPECAOVDZTLZ-UHFFFAOYSA-N 0.000 claims description 3
- IPRJQAFWQXYHRS-UHFFFAOYSA-N benzyl (ne)-n-[amino-[3-(2-aminoethyl)pyrrolidin-1-yl]methylidene]carbamate Chemical compound C1C(CCN)CCN1C(=N)NC(=O)OCC1=CC=CC=C1 IPRJQAFWQXYHRS-UHFFFAOYSA-N 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- KHGOQBXPPQSAHA-UHFFFAOYSA-N [N]C(N)=N Chemical compound [N]C(N)=N KHGOQBXPPQSAHA-UHFFFAOYSA-N 0.000 claims description 2
- 125000006242 amine protecting group Chemical group 0.000 claims description 2
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 claims description 2
- 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims 3
- 229940127090 anticoagulant agent Drugs 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 claims 1
- 241000125205 Anethum Species 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 12
- 229940127219 anticoagulant drug Drugs 0.000 abstract description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 6
- 201000010099 disease Diseases 0.000 abstract description 5
- 230000002265 prevention Effects 0.000 abstract description 5
- 108010036927 trypsin-like serine protease Proteins 0.000 abstract description 3
- 230000002860 competitive effect Effects 0.000 abstract description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 480
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 309
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 276
- 239000002904 solvent Substances 0.000 description 264
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 258
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 247
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 238
- 238000005160 1H NMR spectroscopy Methods 0.000 description 176
- 235000019439 ethyl acetate Nutrition 0.000 description 175
- 239000000243 solution Substances 0.000 description 175
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 171
- 239000000047 product Substances 0.000 description 133
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 117
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 114
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 113
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 106
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 100
- 239000011734 sodium Substances 0.000 description 92
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 88
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 86
- 239000003480 eluent Substances 0.000 description 83
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 78
- VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical compound [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 description 77
- 150000001409 amidines Chemical class 0.000 description 74
- 238000002360 preparation method Methods 0.000 description 73
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 72
- 239000011541 reaction mixture Substances 0.000 description 72
- 238000003818 flash chromatography Methods 0.000 description 66
- 239000003054 catalyst Substances 0.000 description 64
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 63
- 229910052763 palladium Inorganic materials 0.000 description 63
- 239000012074 organic phase Substances 0.000 description 59
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 58
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 55
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 51
- 239000012267 brine Substances 0.000 description 50
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 50
- 239000012044 organic layer Substances 0.000 description 47
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 45
- 238000003756 stirring Methods 0.000 description 44
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 43
- 229910000027 potassium carbonate Inorganic materials 0.000 description 41
- 239000010410 layer Substances 0.000 description 38
- 239000012043 crude product Substances 0.000 description 35
- 229920006395 saturated elastomer Polymers 0.000 description 34
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 31
- 238000001704 evaporation Methods 0.000 description 28
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 27
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 26
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 25
- 238000000746 purification Methods 0.000 description 25
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 24
- 239000008346 aqueous phase Substances 0.000 description 22
- 230000008020 evaporation Effects 0.000 description 22
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 22
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 21
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 20
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 19
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 19
- 238000004587 chromatography analysis Methods 0.000 description 18
- 238000004108 freeze drying Methods 0.000 description 18
- 239000003921 oil Substances 0.000 description 18
- 239000012071 phase Substances 0.000 description 17
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 17
- 229910000029 sodium carbonate Inorganic materials 0.000 description 17
- GCTPMLUUWLLESL-UHFFFAOYSA-N benzyl prop-2-enoate Chemical compound C=CC(=O)OCC1=CC=CC=C1 GCTPMLUUWLLESL-UHFFFAOYSA-N 0.000 description 16
- 238000001914 filtration Methods 0.000 description 16
- 238000000926 separation method Methods 0.000 description 16
- 239000002002 slurry Substances 0.000 description 16
- 238000005481 NMR spectroscopy Methods 0.000 description 14
- 238000001035 drying Methods 0.000 description 14
- 239000000284 extract Substances 0.000 description 14
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 14
- 239000000843 powder Substances 0.000 description 14
- 229910004373 HOAc Inorganic materials 0.000 description 13
- 239000013078 crystal Substances 0.000 description 13
- 238000005984 hydrogenation reaction Methods 0.000 description 13
- 125000003386 piperidinyl group Chemical group 0.000 description 13
- 239000007787 solid Substances 0.000 description 13
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 12
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 12
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 12
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 12
- 239000007789 gas Substances 0.000 description 12
- 239000002244 precipitate Substances 0.000 description 11
- 239000000741 silica gel Substances 0.000 description 11
- 229910002027 silica gel Inorganic materials 0.000 description 11
- 229960001866 silicon dioxide Drugs 0.000 description 11
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 10
- 102000001399 Kallikrein Human genes 0.000 description 10
- 108060005987 Kallikrein Proteins 0.000 description 10
- 239000002253 acid Substances 0.000 description 10
- 239000001257 hydrogen Substances 0.000 description 10
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 9
- JHVLLYQQQYIWKX-UHFFFAOYSA-N benzyl 2-bromoacetate Chemical compound BrCC(=O)OCC1=CC=CC=C1 JHVLLYQQQYIWKX-UHFFFAOYSA-N 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 8
- 229940024606 amino acid Drugs 0.000 description 8
- 150000001721 carbon Chemical group 0.000 description 8
- 238000001816 cooling Methods 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 238000010992 reflux Methods 0.000 description 8
- 239000012258 stirred mixture Substances 0.000 description 8
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 239000013058 crude material Substances 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 235000017557 sodium bicarbonate Nutrition 0.000 description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 102100035792 Kininogen-1 Human genes 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 6
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- 208000007536 Thrombosis Diseases 0.000 description 6
- 229940022663 acetate Drugs 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 230000003389 potentiating effect Effects 0.000 description 6
- 150000003254 radicals Chemical class 0.000 description 6
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical group CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- 102000012479 Serine Proteases Human genes 0.000 description 5
- 108010022999 Serine Proteases Proteins 0.000 description 5
- 230000002378 acidificating effect Effects 0.000 description 5
- 239000012298 atmosphere Substances 0.000 description 5
- CPZVJYPXOWWFSW-QXMHVHEDSA-N dibenzyl (z)-but-2-enedioate Chemical compound C=1C=CC=CC=1COC(=O)\C=C/C(=O)OCC1=CC=CC=C1 CPZVJYPXOWWFSW-QXMHVHEDSA-N 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- XBXCNNQPRYLIDE-UHFFFAOYSA-M n-tert-butylcarbamate Chemical compound CC(C)(C)NC([O-])=O XBXCNNQPRYLIDE-UHFFFAOYSA-M 0.000 description 5
- 239000011736 potassium bicarbonate Substances 0.000 description 5
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 5
- 239000010948 rhodium Substances 0.000 description 5
- 239000000377 silicon dioxide Substances 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 229910052938 sodium sulfate Inorganic materials 0.000 description 5
- 235000011152 sodium sulphate Nutrition 0.000 description 5
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 4
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 4
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 4
- 108010073385 Fibrin Proteins 0.000 description 4
- 102000009123 Fibrin Human genes 0.000 description 4
- 108010093008 Kinins Proteins 0.000 description 4
- 102000002397 Kinins Human genes 0.000 description 4
- 229910010082 LiAlH Inorganic materials 0.000 description 4
- GKZIWHRNKRBEOH-HOTGVXAUSA-N Phe-Phe Chemical compound C([C@H]([NH3+])C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)C1=CC=CC=C1 GKZIWHRNKRBEOH-HOTGVXAUSA-N 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 208000006673 asthma Diseases 0.000 description 4
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 4
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 4
- 229950003499 fibrin Drugs 0.000 description 4
- 229940039088 kininogenase Drugs 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 4
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 4
- 208000010125 myocardial infarction Diseases 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- 239000000052 vinegar Substances 0.000 description 4
- 235000021419 vinegar Nutrition 0.000 description 4
- JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 3
- 101800004538 Bradykinin Proteins 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
- 235000001258 Cinchona calisaya Nutrition 0.000 description 3
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 3
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 3
- FYSKZKQBTVLYEQ-FSLKYBNLSA-N Kallidin Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)CCC1 FYSKZKQBTVLYEQ-FSLKYBNLSA-N 0.000 description 3
- 108010003195 Kallidin Proteins 0.000 description 3
- 108010077861 Kininogens Proteins 0.000 description 3
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- ZNVFLLSINDBVIU-UHFFFAOYSA-N benzyl n-[amino-[3-(azidomethyl)pyrrolidin-1-yl]methylidene]carbamate Chemical compound C1CC(CN=[N+]=[N-])CN1C(=N)NC(=O)OCC1=CC=CC=C1 ZNVFLLSINDBVIU-UHFFFAOYSA-N 0.000 description 3
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 3
- 230000005587 bubbling Effects 0.000 description 3
- 235000011089 carbon dioxide Nutrition 0.000 description 3
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 3
- 230000015271 coagulation Effects 0.000 description 3
- 238000005345 coagulation Methods 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- VDQVEACBQKUUSU-UHFFFAOYSA-M disodium;sulfanide Chemical compound [Na+].[Na+].[SH-] VDQVEACBQKUUSU-UHFFFAOYSA-M 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000012065 filter cake Substances 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 3
- 239000005457 ice water Substances 0.000 description 3
- 208000027866 inflammatory disease Diseases 0.000 description 3
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 3
- FBKRSZZALAQRNH-IRXDYDNUSA-N methyl (2s)-2-[[(2s)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoate Chemical compound C([C@@H](C(=O)OC)NC(=O)[C@@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FBKRSZZALAQRNH-IRXDYDNUSA-N 0.000 description 3
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 3
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical group C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 3
- 108010023688 phenylalanylphenylalanine methyl ester Proteins 0.000 description 3
- CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 3
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 3
- 229960002429 proline Drugs 0.000 description 3
- 238000010791 quenching Methods 0.000 description 3
- 229960000948 quinine Drugs 0.000 description 3
- 206010039083 rhinitis Diseases 0.000 description 3
- 229910052703 rhodium Inorganic materials 0.000 description 3
- 235000004400 serine Nutrition 0.000 description 3
- MNWBNISUBARLIT-UHFFFAOYSA-N sodium cyanide Chemical compound [Na+].N#[C-] MNWBNISUBARLIT-UHFFFAOYSA-N 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 229910052979 sodium sulfide Inorganic materials 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- 201000005665 thrombophilia Diseases 0.000 description 3
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 2
- BSVIAHLFUOLJKY-UHFFFAOYSA-N 2-(1-benzhydrylazetidin-3-yl)ethanamine Chemical compound C1C(CCN)CN1C(C=1C=CC=CC=1)C1=CC=CC=C1 BSVIAHLFUOLJKY-UHFFFAOYSA-N 0.000 description 2
- GUGQQGROXHPINL-UHFFFAOYSA-N 2-oxobutanoyl chloride Chemical compound CCC(=O)C(Cl)=O GUGQQGROXHPINL-UHFFFAOYSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- JKGDBZVNKGWSJD-UHFFFAOYSA-N 4-(azidomethyl)benzenecarboximidamide Chemical compound NC(=N)C1=CC=C(CN=[N+]=[N-])C=C1 JKGDBZVNKGWSJD-UHFFFAOYSA-N 0.000 description 2
- UZFMOKQJFYMBGY-UHFFFAOYSA-N 4-hydroxy-TEMPO Chemical compound CC1(C)CC(O)CC(C)(C)N1[O] UZFMOKQJFYMBGY-UHFFFAOYSA-N 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 206010003178 Arterial thrombosis Diseases 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- QDXDGLPNOSUQOM-UHFFFAOYSA-N C(C1=CC=CC=C1)OC(=O)NC(=N)N1CCCCC1.CN(C=O)C Chemical compound C(C1=CC=CC=C1)OC(=O)NC(=N)N1CCCCC1.CN(C=O)C QDXDGLPNOSUQOM-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 229940127379 Kallikrein Inhibitors Drugs 0.000 description 2
- 102100038297 Kallikrein-1 Human genes 0.000 description 2
- 101710176219 Kallikrein-1 Proteins 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 2
- 206010033645 Pancreatitis Diseases 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 208000010378 Pulmonary Embolism Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 108060005989 Tryptase Proteins 0.000 description 2
- 102000001400 Tryptase Human genes 0.000 description 2
- 208000024780 Urticaria Diseases 0.000 description 2
- 206010047249 Venous thrombosis Diseases 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000012300 argon atmosphere Substances 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- UDLLFLQFQMACJB-UHFFFAOYSA-N azidomethylbenzene Chemical compound [N-]=[N+]=NCC1=CC=CC=C1 UDLLFLQFQMACJB-UHFFFAOYSA-N 0.000 description 2
- YMWXGENNQHURTE-UHFFFAOYSA-N benzyl (ne)-n-[amino-[3-(aminomethyl)pyrrolidin-1-yl]methylidene]carbamate Chemical compound C1C(CN)CCN1C(=N)NC(=O)OCC1=CC=CC=C1 YMWXGENNQHURTE-UHFFFAOYSA-N 0.000 description 2
- XHSYAQAQUOUGFP-UHFFFAOYSA-N benzyl (ne)-n-[amino-[4-(2-aminoethyl)piperidin-1-yl]methylidene]carbamate Chemical compound C1CC(CCN)CCN1C(=N)NC(=O)OCC1=CC=CC=C1 XHSYAQAQUOUGFP-UHFFFAOYSA-N 0.000 description 2
- QUKGYYKBILRGFE-UHFFFAOYSA-N benzyl acetate Chemical compound CC(=O)OCC1=CC=CC=C1 QUKGYYKBILRGFE-UHFFFAOYSA-N 0.000 description 2
- RELQNVJWEQKPEA-UHFFFAOYSA-N benzyl n-[amino-[4-(aminomethyl)phenyl]methylidene]carbamate Chemical compound C1=CC(CN)=CC=C1C(=N)NC(=O)OCC1=CC=CC=C1 RELQNVJWEQKPEA-UHFFFAOYSA-N 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 238000004517 catalytic hydrocracking Methods 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 229910052593 corundum Inorganic materials 0.000 description 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 230000000155 isotopic effect Effects 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- AMXOYNBUYSYVKV-UHFFFAOYSA-M lithium bromide Chemical compound [Li+].[Br-] AMXOYNBUYSYVKV-UHFFFAOYSA-M 0.000 description 2
- HSZCZNFXUDYRKD-UHFFFAOYSA-M lithium iodide Chemical compound [Li+].[I-] HSZCZNFXUDYRKD-UHFFFAOYSA-M 0.000 description 2
- VCZANKJSRYTJDN-STQMWFEESA-N methyl (2s)-3-phenyl-2-[[(2s)-pyrrolidine-2-carbonyl]amino]propanoate Chemical compound C([C@@H](C(=O)OC)NC(=O)[C@H]1NCCC1)C1=CC=CC=C1 VCZANKJSRYTJDN-STQMWFEESA-N 0.000 description 2
- 229940050176 methyl chloride Drugs 0.000 description 2
- 150000004702 methyl esters Chemical class 0.000 description 2
- 239000012452 mother liquor Substances 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 2
- 238000005192 partition Methods 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 229940126155 plasma kallikrein inhibitor Drugs 0.000 description 2
- 231100000572 poisoning Toxicity 0.000 description 2
- 230000000607 poisoning effect Effects 0.000 description 2
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 2
- 239000012047 saturated solution Substances 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000000935 solvent evaporation Methods 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- MOLUHRBHXXGWDP-UHFFFAOYSA-N tert-butyl n-(azetidin-3-ylmethyl)carbamate Chemical compound CC(C)(C)OC(=O)NCC1CNC1 MOLUHRBHXXGWDP-UHFFFAOYSA-N 0.000 description 2
- VHYXAWLOJGIJPC-UHFFFAOYSA-N tert-butyl n-(piperidin-4-ylmethyl)carbamate Chemical compound CC(C)(C)OC(=O)NCC1CCNCC1 VHYXAWLOJGIJPC-UHFFFAOYSA-N 0.000 description 2
- 238000001214 thermospray mass spectrometry Methods 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical class NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000012876 topography Methods 0.000 description 2
- WJKHJLXJJJATHN-UHFFFAOYSA-N trifluoromethanesulfonic anhydride Substances FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 2
- 230000001810 trypsinlike Effects 0.000 description 2
- 230000008728 vascular permeability Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 229910001845 yogo sapphire Inorganic materials 0.000 description 2
- KISVATOISQDZJU-UHFFFAOYSA-N (1-benzhydrylazetidin-3-yl)methanamine Chemical compound C1C(CN)CN1C(C=1C=CC=CC=1)C1=CC=CC=C1 KISVATOISQDZJU-UHFFFAOYSA-N 0.000 description 1
- ZRACFKBMLJSUJO-UHFFFAOYSA-N (1-benzylpyrrolidin-3-yl)methanol pyrrolidin-3-ylmethanol Chemical compound C(C1=CC=CC=C1)N1CC(CC1)CO.OCC1CNCC1 ZRACFKBMLJSUJO-UHFFFAOYSA-N 0.000 description 1
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 1
- SSXPFNXUSFJJEI-BHEJXMHWSA-N (2s)-2-[[(2s)-2-[[(2s)-1-[(2s)-2-[[(2s)-2-[[2-[[(2s)-1-[(2s)-1-[(2s)-2-[[(2s)-6-amino-2-[[(2s)-2-amino-4-methylsulfanylbutanoyl]amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-3- Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)CCC1 SSXPFNXUSFJJEI-BHEJXMHWSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- XJLSEXAGTJCILF-RXMQYKEDSA-N (R)-nipecotic acid zwitterion Chemical compound OC(=O)[C@@H]1CCCNC1 XJLSEXAGTJCILF-RXMQYKEDSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- BKTLZMDEVMKAPE-UHFFFAOYSA-N 1-benzhydryl-2-methylazetidine Chemical compound CC1CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 BKTLZMDEVMKAPE-UHFFFAOYSA-N 0.000 description 1
- QWGYCLIMHHUXSL-UHFFFAOYSA-N 1-benzyl-3-(chloromethyl)pyrrolidine Chemical compound C1C(CCl)CCN1CC1=CC=CC=C1 QWGYCLIMHHUXSL-UHFFFAOYSA-N 0.000 description 1
- ANOOTOPTCJRUPK-UHFFFAOYSA-N 1-iodohexane Chemical compound CCCCCCI ANOOTOPTCJRUPK-UHFFFAOYSA-N 0.000 description 1
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 1
- LJQRIZHZZWBLOK-UHFFFAOYSA-N 2-(1-benzhydrylazetidin-3-yl)acetonitrile Chemical compound C1C(CC#N)CN1C(C=1C=CC=CC=1)C1=CC=CC=C1 LJQRIZHZZWBLOK-UHFFFAOYSA-N 0.000 description 1
- HYBXAXKMVJEWHM-UHFFFAOYSA-N 2-(1-benzylpyrrolidin-3-yl)acetonitrile Chemical compound C1C(CC#N)CCN1CC1=CC=CC=C1 HYBXAXKMVJEWHM-UHFFFAOYSA-N 0.000 description 1
- VNDNKFJKUBLYQB-UHFFFAOYSA-N 2-(4-amino-6-chloro-5-oxohexyl)guanidine Chemical compound ClCC(=O)C(N)CCCN=C(N)N VNDNKFJKUBLYQB-UHFFFAOYSA-N 0.000 description 1
- ZMCXBBDKHWNUHS-UHFFFAOYSA-N 2-azido-2-phenylethanimidamide Chemical compound C(N)(=N)C(C1=CC=CC=C1)N=[N+]=[N-] ZMCXBBDKHWNUHS-UHFFFAOYSA-N 0.000 description 1
- KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 description 1
- LDSQQXKSEFZAPE-UHFFFAOYSA-N 2-piperidin-4-ylethanol Chemical compound OCCC1CCNCC1 LDSQQXKSEFZAPE-UHFFFAOYSA-N 0.000 description 1
- ZSLUVFAKFWKJRC-IGMARMGPSA-N 232Th Chemical compound [232Th] ZSLUVFAKFWKJRC-IGMARMGPSA-N 0.000 description 1
- IANPHULUNXCOEH-UHFFFAOYSA-N 3-(2-aminoethyl)azetidine-1-carboximidamide Chemical compound NCCC1CN(C(N)=N)C1 IANPHULUNXCOEH-UHFFFAOYSA-N 0.000 description 1
- ANAISECDQAJCJT-UHFFFAOYSA-N 3-(2-aminoethyl)pyrrolidine-1-carboximidamide Chemical compound NCCC1CCN(C(N)=N)C1 ANAISECDQAJCJT-UHFFFAOYSA-N 0.000 description 1
- NXBXVYSSRULMKX-UHFFFAOYSA-N 3-(aminomethyl)azetidine-1-carboximidamide Chemical compound NCC1CN(C(N)=N)C1 NXBXVYSSRULMKX-UHFFFAOYSA-N 0.000 description 1
- BDMCYYVDQYLMOQ-UHFFFAOYSA-N 3-(aminomethyl)pyrrolidine-1-carboximidamide Chemical compound NCC1CCN(C(N)=N)C1 BDMCYYVDQYLMOQ-UHFFFAOYSA-N 0.000 description 1
- GWVIVHINAVAKKV-UHFFFAOYSA-N 4-(azidomethyl)benzonitrile Chemical compound [N-]=[N+]=NCC1=CC=C(C#N)C=C1 GWVIVHINAVAKKV-UHFFFAOYSA-N 0.000 description 1
- UMLFTCYAQPPZER-UHFFFAOYSA-N 4-(bromomethyl)benzonitrile Chemical compound BrCC1=CC=C(C#N)C=C1 UMLFTCYAQPPZER-UHFFFAOYSA-N 0.000 description 1
- PTCSSXYPZOFISK-UHFFFAOYSA-N 4-chlorosulfonylbenzoic acid Chemical compound OC(=O)C1=CC=C(S(Cl)(=O)=O)C=C1 PTCSSXYPZOFISK-UHFFFAOYSA-N 0.000 description 1
- GOJHDSPKKWASRH-UHFFFAOYSA-N 5-amino-2-(4-aminophenyl)benzonitrile Chemical compound C1=CC(N)=CC=C1C1=CC=C(N)C=C1C#N GOJHDSPKKWASRH-UHFFFAOYSA-N 0.000 description 1
- VWXGRWMELBPMCU-UHFFFAOYSA-N 5-chloro-1-[3-(dimethylamino)propyl]-3-phenylbenzimidazol-2-one Chemical compound O=C1N(CCCN(C)C)C2=CC=C(Cl)C=C2N1C1=CC=CC=C1 VWXGRWMELBPMCU-UHFFFAOYSA-N 0.000 description 1
- KKJUPNGICOCCDW-UHFFFAOYSA-N 7-N,N-Dimethylamino-1,2,3,4,5-pentathiocyclooctane Chemical compound CN(C)C1CSSSSSC1 KKJUPNGICOCCDW-UHFFFAOYSA-N 0.000 description 1
- QYPPJABKJHAVHS-UHFFFAOYSA-N Agmatine Natural products NCCCCNC(N)=N QYPPJABKJHAVHS-UHFFFAOYSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 206010002388 Angina unstable Diseases 0.000 description 1
- IJYZHIOOBGIINM-WDSKDSINSA-N Arg-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCN=C(N)N IJYZHIOOBGIINM-WDSKDSINSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- JXYACYYPACQCDM-UHFFFAOYSA-N Benzyl glycinate Chemical compound NCC(=O)OCC1=CC=CC=C1 JXYACYYPACQCDM-UHFFFAOYSA-N 0.000 description 1
- LINJSZAHJMHGDR-UHFFFAOYSA-N C(C1=CC=CC=C1)N1CC(CC1)CCN.N1CCCC1 Chemical compound C(C1=CC=CC=C1)N1CC(CC1)CCN.N1CCCC1 LINJSZAHJMHGDR-UHFFFAOYSA-N 0.000 description 1
- UHFNFTGGSORNFB-UHFFFAOYSA-N C(C1=CC=CC=C1)N1CC(CC1)CCl.C(C1=CC=CC=C1)N1CC(CC1)CC#N Chemical compound C(C1=CC=CC=C1)N1CC(CC1)CCl.C(C1=CC=CC=C1)N1CC(CC1)CC#N UHFNFTGGSORNFB-UHFFFAOYSA-N 0.000 description 1
- DHJPREDXQQDZDM-UHFFFAOYSA-N C1=CC=C(C=C1)CC2=C(OC=C2)OC(C(=O)O)(OC3=CC=CO3)OC4=CC=CO4 Chemical compound C1=CC=C(C=C1)CC2=C(OC=C2)OC(C(=O)O)(OC3=CC=CO3)OC4=CC=CO4 DHJPREDXQQDZDM-UHFFFAOYSA-N 0.000 description 1
- 208000021910 Cerebral Arterial disease Diseases 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- 241000511343 Chondrostoma nasus Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- OPFTUNCRGUEPRZ-QLFBSQMISA-N Cyclohexane Natural products CC(=C)[C@@H]1CC[C@@](C)(C=C)[C@H](C(C)=C)C1 OPFTUNCRGUEPRZ-QLFBSQMISA-N 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 108010062466 Enzyme Precursors Proteins 0.000 description 1
- 102000010911 Enzyme Precursors Human genes 0.000 description 1
- 241000238558 Eucarida Species 0.000 description 1
- 206010015866 Extravasation Diseases 0.000 description 1
- 108010014172 Factor V Proteins 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 108010071289 Factor XIII Proteins 0.000 description 1
- 108010000487 High-Molecular-Weight Kininogen Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- 102000010631 Kininogens Human genes 0.000 description 1
- 229930182821 L-proline Natural products 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 238000005684 Liebig rearrangement reaction Methods 0.000 description 1
- 108010058188 Low-Molecular-Weight Kininogen Proteins 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 108700018740 Met-Lys- bradykinin Proteins 0.000 description 1
- KQJQICVXLJTWQD-UHFFFAOYSA-N N-Methylthiourea Chemical compound CNC(N)=S KQJQICVXLJTWQD-UHFFFAOYSA-N 0.000 description 1
- ZSMBKZXCRLRDPA-UHFFFAOYSA-N NCC1=CC=C(C=C1)C(N(C(=O)OCC1=CC=CC=C1)C(=O)OCC1=CC=CC=C1)=N Chemical compound NCC1=CC=C(C=C1)C(N(C(=O)OCC1=CC=CC=C1)C(=O)OCC1=CC=CC=C1)=N ZSMBKZXCRLRDPA-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 240000000220 Panda oleosa Species 0.000 description 1
- 235000016496 Panda oleosa Nutrition 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 description 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 1
- GLUYKHMBGKQBHE-JYJNAYRXSA-N Phe-Val-Arg Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CC1=CC=CC=C1 GLUYKHMBGKQBHE-JYJNAYRXSA-N 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- 102000003827 Plasma Kallikrein Human genes 0.000 description 1
- 108090000113 Plasma Kallikrein Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 206010038563 Reocclusion Diseases 0.000 description 1
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- 229910052776 Thorium Inorganic materials 0.000 description 1
- 206010043647 Thrombotic Stroke Diseases 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- JUNBYRXGWOTEEP-UHFFFAOYSA-N [C].NC(N)=N Chemical compound [C].NC(N)=N JUNBYRXGWOTEEP-UHFFFAOYSA-N 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 239000012445 acidic reagent Substances 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- QYPPJABKJHAVHS-UHFFFAOYSA-P agmatinium(2+) Chemical compound NC(=[NH2+])NCCCC[NH3+] QYPPJABKJHAVHS-UHFFFAOYSA-P 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- IYABWNGZIDDRAK-UHFFFAOYSA-N allene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 150000001483 arginine derivatives Chemical class 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- IADUEWIQBXOCDZ-UHFFFAOYSA-N azetidine-2-carboxylic acid Chemical compound OC(=O)C1CCN1 IADUEWIQBXOCDZ-UHFFFAOYSA-N 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- YWSUJANPSJZCGM-UHFFFAOYSA-N azidomethylbenzene hydrochloride Chemical compound C1=CC=C(C=C1)CN=[N+]=[N-].Cl YWSUJANPSJZCGM-UHFFFAOYSA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- LWKVJCNBARLWPJ-UHFFFAOYSA-N benzyl (ne)-n-[amino(piperidin-1-yl)methylidene]carbamate Chemical compound C1CCCCN1C(N)=NC(=O)OCC1=CC=CC=C1 LWKVJCNBARLWPJ-UHFFFAOYSA-N 0.000 description 1
- WKNMVKCFLWZMKY-UHFFFAOYSA-N benzyl (ne)-n-[amino-[3-(2-aminoethyl)azetidin-1-yl]methylidene]carbamate Chemical compound C1C(CCN)CN1C(=N)NC(=O)OCC1=CC=CC=C1 WKNMVKCFLWZMKY-UHFFFAOYSA-N 0.000 description 1
- POIKVYJGWFDRKU-UHFFFAOYSA-N benzyl (ne)-n-[amino-[3-(aminomethyl)azetidin-1-yl]methylidene]carbamate Chemical compound C1C(CN)CN1C(=N)NC(=O)OCC1=CC=CC=C1 POIKVYJGWFDRKU-UHFFFAOYSA-N 0.000 description 1
- ZXUWMQMZIJTBGY-UHFFFAOYSA-N benzyl (ne)-n-[amino-[3-[2-[(2-methylpropan-2-yl)oxycarbonylamino]ethyl]azetidin-1-yl]methylidene]carbamate Chemical compound C1C(CCNC(=O)OC(C)(C)C)CN1C(N)=NC(=O)OCC1=CC=CC=C1 ZXUWMQMZIJTBGY-UHFFFAOYSA-N 0.000 description 1
- KIEVFZUZTGKPNW-UHFFFAOYSA-N benzyl (ne)-n-[amino-[3-[[(2-methylpropan-2-yl)oxycarbonylamino]methyl]azetidin-1-yl]methylidene]carbamate Chemical compound C1C(CNC(=O)OC(C)(C)C)CN1C(N)=NC(=O)OCC1=CC=CC=C1 KIEVFZUZTGKPNW-UHFFFAOYSA-N 0.000 description 1
- MLYVUDZUFYUWHE-UHFFFAOYSA-N benzyl (nz)-n-[amino(methoxy)methylidene]carbamate Chemical compound COC(N)=NC(=O)OCC1=CC=CC=C1 MLYVUDZUFYUWHE-UHFFFAOYSA-N 0.000 description 1
- ZHNUXJSPYNQQHV-UHFFFAOYSA-N benzyl (nz)-n-[amino(methylsulfanyl)methylidene]carbamate Chemical compound CSC(=N)NC(=O)OCC1=CC=CC=C1 ZHNUXJSPYNQQHV-UHFFFAOYSA-N 0.000 description 1
- WNYDFVKRTSLYIJ-UHFFFAOYSA-N benzyl (nz)-n-[amino-[3-(hydroxymethyl)pyrrolidin-1-yl]methylidene]carbamate Chemical compound C1C(CO)CCN1C(=N)NC(=O)OCC1=CC=CC=C1 WNYDFVKRTSLYIJ-UHFFFAOYSA-N 0.000 description 1
- KHSASPISVMGYIF-UHFFFAOYSA-N benzyl (nz)-n-[amino-[4-[[(2-methylpropan-2-yl)oxycarbonylamino]methyl]piperidin-1-yl]methylidene]carbamate Chemical compound C1CC(CNC(=O)OC(C)(C)C)CCN1C(N)=NC(=O)OCC1=CC=CC=C1 KHSASPISVMGYIF-UHFFFAOYSA-N 0.000 description 1
- ZWMHGRPQEGZNNW-UHFFFAOYSA-N benzyl 2-(trifluoromethylsulfonyloxy)acetate Chemical compound FC(F)(F)S(=O)(=O)OCC(=O)OCC1=CC=CC=C1 ZWMHGRPQEGZNNW-UHFFFAOYSA-N 0.000 description 1
- UFSFLPLVPKCPMC-UHFFFAOYSA-N benzyl N-[4-(aminomethyl)cyclohexanecarboximidoyl]-N-phenylmethoxycarbonylcarbamate Chemical compound C1CC(CN)CCC1C(=N)N(C(=O)OCC=1C=CC=CC=1)C(=O)OCC1=CC=CC=C1 UFSFLPLVPKCPMC-UHFFFAOYSA-N 0.000 description 1
- 229940007550 benzyl acetate Drugs 0.000 description 1
- ULHSMCITWCUOSA-UHFFFAOYSA-N benzyl n-[[3-(2-aminoethyl)azetidin-1-yl]-(phenylmethoxycarbonylamino)methylidene]carbamate Chemical compound C1C(CCN)CN1C(NC(=O)OCC=1C=CC=CC=1)=NC(=O)OCC1=CC=CC=C1 ULHSMCITWCUOSA-UHFFFAOYSA-N 0.000 description 1
- YQICJBRATOLJFE-UHFFFAOYSA-N benzyl n-[[3-(aminomethyl)azetidin-1-yl]-(phenylmethoxycarbonylamino)methylidene]carbamate Chemical compound C1C(CN)CN1C(NC(=O)OCC=1C=CC=CC=1)=NC(=O)OCC1=CC=CC=C1 YQICJBRATOLJFE-UHFFFAOYSA-N 0.000 description 1
- IZHWHSBRJZEGIO-UHFFFAOYSA-N benzyl n-[amino-[4-(2-azidoethyl)piperidin-1-yl]methylidene]carbamate Chemical compound C1CC(CCN=[N+]=[N-])CCN1C(=N)NC(=O)OCC1=CC=CC=C1 IZHWHSBRJZEGIO-UHFFFAOYSA-N 0.000 description 1
- DPYMTGLUMLGWDO-UHFFFAOYSA-N benzyl n-[amino-[4-(aminomethyl)piperidin-1-yl]methylidene]carbamate Chemical compound C1CC(CN)CCN1C(=N)NC(=O)OCC1=CC=CC=C1 DPYMTGLUMLGWDO-UHFFFAOYSA-N 0.000 description 1
- YDPYKRRABLKYNU-UHFFFAOYSA-N benzyl n-[amino-[4-(azidomethyl)phenyl]methylidene]carbamate Chemical compound C=1C=C(CN=[N+]=[N-])C=CC=1C(=N)NC(=O)OCC1=CC=CC=C1 YDPYKRRABLKYNU-UHFFFAOYSA-N 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 150000001642 boronic acid derivatives Chemical group 0.000 description 1
- KDPAWGWELVVRCH-UHFFFAOYSA-N bromoacetic acid Chemical compound OC(=O)CBr KDPAWGWELVVRCH-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- VFGRALUHHHDIQI-UHFFFAOYSA-N butyl 2-hydroxyacetate Chemical compound CCCCOC(=O)CO VFGRALUHHHDIQI-UHFFFAOYSA-N 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 1
- 206010061592 cardiac fibrillation Diseases 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 238000013130 cardiovascular surgery Methods 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- VXIVSQZSERGHQP-UHFFFAOYSA-N chloroacetamide Chemical compound NC(=O)CCl VXIVSQZSERGHQP-UHFFFAOYSA-N 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 125000003963 dichloro group Chemical group Cl* 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 208000009190 disseminated intravascular coagulation Diseases 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- QWFJZCGIJRHYDQ-UHFFFAOYSA-N ethyl 2-(trifluoromethylsulfonyloxy)acetate Chemical compound CCOC(=O)COS(=O)(=O)C(F)(F)F QWFJZCGIJRHYDQ-UHFFFAOYSA-N 0.000 description 1
- ZANNOFHADGWOLI-UHFFFAOYSA-N ethyl 2-hydroxyacetate Chemical compound CCOC(=O)CO ZANNOFHADGWOLI-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 230000036251 extravasation Effects 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 229940012444 factor xiii Drugs 0.000 description 1
- 230000002600 fibrillogenic effect Effects 0.000 description 1
- 108010073651 fibrinmonomer Proteins 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 210000002837 heart atrium Anatomy 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- QBNWFVUMKJIMAX-UHFFFAOYSA-N hexyl 2-hydroxyacetate Chemical compound CCCCCCOC(=O)CO QBNWFVUMKJIMAX-UHFFFAOYSA-N 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- HXEACLLIILLPRG-RXMQYKEDSA-N l-pipecolic acid Natural products OC(=O)[C@H]1CCCCN1 HXEACLLIILLPRG-RXMQYKEDSA-N 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- KUGLDBMQKZTXPW-JEDNCBNOSA-N methyl (2s)-2-amino-3-methylbutanoate;hydrochloride Chemical compound Cl.COC(=O)[C@@H](N)C(C)C KUGLDBMQKZTXPW-JEDNCBNOSA-N 0.000 description 1
- APCHKWZTSCBBJX-RGMNGODLSA-N methyl (2s)-piperidine-2-carboxylate;hydrochloride Chemical compound [Cl-].COC(=O)[C@@H]1CCCC[NH2+]1 APCHKWZTSCBBJX-RGMNGODLSA-N 0.000 description 1
- PPYPHCLFWPCGAU-UHFFFAOYSA-N methyl 2-(trifluoromethylsulfonyloxy)acetate Chemical compound COC(=O)COS(=O)(=O)C(F)(F)F PPYPHCLFWPCGAU-UHFFFAOYSA-N 0.000 description 1
- ZXUQEPZWVQIOJE-UHFFFAOYSA-N methyl 2-chloro-2-oxoacetate Chemical compound COC(=O)C(Cl)=O ZXUQEPZWVQIOJE-UHFFFAOYSA-N 0.000 description 1
- GSYSFVSGPABNNL-UHFFFAOYSA-N methyl 2-dimethoxyphosphoryl-2-(phenylmethoxycarbonylamino)acetate Chemical group COC(=O)C(P(=O)(OC)OC)NC(=O)OCC1=CC=CC=C1 GSYSFVSGPABNNL-UHFFFAOYSA-N 0.000 description 1
- VSDUZFOSJDMAFZ-VIFPVBQESA-N methyl L-phenylalaninate Chemical compound COC(=O)[C@@H](N)CC1=CC=CC=C1 VSDUZFOSJDMAFZ-VIFPVBQESA-N 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 238000002406 microsurgery Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- BDRTVPCFKSUHCJ-UHFFFAOYSA-N molecular hydrogen;potassium Chemical compound [K].[H][H] BDRTVPCFKSUHCJ-UHFFFAOYSA-N 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- FEKRFYZGYUTGRY-UHFFFAOYSA-N n'-ethylmethanediimine Chemical compound CCN=C=N FEKRFYZGYUTGRY-UHFFFAOYSA-N 0.000 description 1
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- ZRSNZINYAWTAHE-UHFFFAOYSA-N p-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1 ZRSNZINYAWTAHE-UHFFFAOYSA-N 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000000863 peptide conjugate Substances 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 125000001151 peptidyl group Chemical group 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 description 1
- HXEACLLIILLPRG-UHFFFAOYSA-N pipecolic acid Chemical compound OC(=O)C1CCCCN1 HXEACLLIILLPRG-UHFFFAOYSA-N 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 1
- 229910052939 potassium sulfate Inorganic materials 0.000 description 1
- 235000011151 potassium sulphates Nutrition 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- TXQWFIVRZNOPCK-UHFFFAOYSA-N pyridin-4-ylmethanamine Chemical compound NCC1=CC=NC=C1 TXQWFIVRZNOPCK-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- QOTUIIJRVXKSJU-UHFFFAOYSA-N pyrrolidin-3-ylmethanol Chemical compound OCC1CCNC1 QOTUIIJRVXKSJU-UHFFFAOYSA-N 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- WYROLENTHWJFLR-ACLDMZEESA-N queuine Chemical compound C1=2C(=O)NC(N)=NC=2NC=C1CN[C@H]1C=C[C@H](O)[C@@H]1O WYROLENTHWJFLR-ACLDMZEESA-N 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000006965 reversible inhibition Effects 0.000 description 1
- 229910052707 ruthenium Inorganic materials 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 150000003355 serines Chemical class 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Inorganic materials [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000002195 soluble material Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- KXCFJDZVQLRYSI-UHFFFAOYSA-N tert-butyl n-(pyridin-4-ylmethyl)carbamate Chemical compound CC(C)(C)OC(=O)NCC1=CC=NC=C1 KXCFJDZVQLRYSI-UHFFFAOYSA-N 0.000 description 1
- PCGZIOZHDSVULS-UHFFFAOYSA-N tert-butyl n-[2-(1-benzhydrylazetidin-3-yl)ethyl]carbamate Chemical compound C1C(CCNC(=O)OC(C)(C)C)CN1C(C=1C=CC=CC=1)C1=CC=CC=C1 PCGZIOZHDSVULS-UHFFFAOYSA-N 0.000 description 1
- CSPJUZSNJFANNU-UHFFFAOYSA-N tert-butyl n-[2-(azetidin-3-yl)ethyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCC1CNC1 CSPJUZSNJFANNU-UHFFFAOYSA-N 0.000 description 1
- GKZMPJHVOBVLDF-UHFFFAOYSA-N tert-butylcarbamic acid;hydrochloride Chemical compound Cl.CC(C)(C)NC(O)=O GKZMPJHVOBVLDF-UHFFFAOYSA-N 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000004685 tetrahydrates Chemical class 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 238000007631 vascular surgery Methods 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
- C07D239/12—Nitrogen atoms not forming part of a nitro radical
- C07D239/14—Nitrogen atoms not forming part of a nitro radical with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to said nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/62—Compounds containing any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylcarbamates
- C07C271/64—Y being a hydrogen or a carbon atom, e.g. benzoylcarbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/022—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/022—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2
- C07K5/0222—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2 with the first amino acid being heterocyclic, e.g. Pro, Trp
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
- C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Otolaryngology (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Hydrogenated Pyridines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.一般式 A1-A2-NH-(CH2)n-B 式I 〔式中、 A1は式IIa、IIb、IIc、IIdまたはIIe で表される構造断片を示し、上記式中、 kは0、1、2、3または4であり; mは1、2、3または4であり; qは0、1、2または3であり; R1はH、炭素原子1〜4個を有するアルキル基またはR11OOC−アルキル−( ここでアルキル基は炭素原子1〜4個を有し、カルボニル基に対してα位に置換 されることもあり、そのα置換基は基R17-(CH2)p-であり、ここでpは0、1ま たは2でありそしてR17はメチル、フェニル、OH、COOR12、CONHR12であり、ここ でR12はHまたは炭素原子1〜4個を有するアルキル基であり、そしてR11はHま たは炭素原子1〜6個を有するアルキル基である) を示し、または R1はPh(4-COOR12)-CH2-(ここでR12は前述の定義を有する)を示し、または R1はR13-NH-CO−アルキル−(ここでアルキル基は炭素原子1〜4個を有し 、カルボニルに対してα位に炭素原子1〜4個を有するアルキル基で置換される こともあり、そしてR13はH、炭素原子1〜4個を有するアルキル基または-CH2C OOR12であり、ここでR12は前述の定義を有する)を示し、または R1はR12OOC-CH2-OOC−アルキル−(ここでアルキル基は1〜4個の炭素原子 を有し、カルボニルに対してα位に炭素原子1〜4個を有するアルキル基で置換 されることもあり、そしてR12は前述の定義を有する)を示し、または R1はR14SO2-、Ph(4-COOR12)-SO2-、Ph(3-COOR12)-SO2-、Ph(2-COOR12)-SO2- (ここでR12は前述の定義を有しそしてR14は炭素原子1〜4個を有するアルキル 基である)を示し、または R1は-CO-R15(ここでR15は炭素原子1〜4個を有するアルキル基である)を 示し、または R1は-CO-OR15(ここでR15は前述の定義を有する)を示し、または R1は-CO-(CH2)p-COOR12(ここでR12は前述の定義を有しそしてpは0、1ま たは2である)を示し、または R1は-CH2PO(OR16)2、-CH2SO3Hまたは-CH2-(5-(1H)−テトラゾリル)(ここ でR16は各場合独立していて、H、メチルまたはエチルである)を示し; R2はH、炭素原子1〜4個を有するアルキル基またはR21OOC− アルキル−(ここでアルキル基は炭素原子1〜4個を有し、R21はHまたは炭素 原子1〜4個を有するアルキル基である)を示し; R3は炭素原子1〜4個を有するアルキル基(このアルキル基は1個以上のフ ッ素原子を担持することもある)を示し、または R3はシクロペンチル、シクロヘキシルまたはフェニル基(これらは炭素原子 1〜4個を有するアルキル基で置換されることもある)を示し、または R3はOR31基(ここでR31はHまたは炭素原子1〜4個を有するアルキル基で ある)で置換されたフェニル基を示しそしてkは0または1であり、または R3は1−ナフチルまたは2−ナフチル基を示しそしてkは0または1であり 、または R3はシス−またはトランス−デカリン基を示しそしてkは0または1であり 、または R3は4−ピリジル、3−ピロリジルまたは3−インドリル(これらはOR31基 で置換されることもあり、ここでR31は前述の定義を有する)を示しそしてkは 0または1であり、または R3はSi(Me)3またはCH(R32)2(ここでR32はシクロヘキシルまたはフェニル基 である)を示し; R4はH、炭素原子1〜4個を有するアルキル基、シクロヘキシルまたはフェ ニル基を示し; A2は式IIIa、IIIbまたはIIIc で表される構造断片を示し、ここで上記式中、 pは0、1または2であり; mは1、2、3または4であり; Yはメチレン基を示し;または Yはエチレン基を示しそして得られる5員環は1個以上のフッ素原子、1個 のヒドロキシル基または1個のオキソ基を4−位に担持していることもありまた は不飽和であることもあり、または Yは4−位にヘテロ原子官能性を有して、-CH2-O-、-CH2-S-、CH2-SO-を示 し、または Yはn−プロピレン基を示しそして得られる6員環は1個のフッ素原子、1 個のヒドロキシル基または1個のオキソ基を5−位に、2個のフッ素原子を4− または5−位の一方に担持していることもありまたは4−および5−位が不飽和 であることもあり、または炭素原子1〜4個を有するアルキル基を4−位に担持 していることもあり、または Yは-CH2-O-CH2-、-CH2-S-CH2-、CH2-SO-CH2-を示し、または Yは-CH2-CH2-CH2-CH2-を示し; R3は前述の定義を有し; R5はHまたは炭素原子1〜4個を有するアルキル基を示し、ま たは R5は-(CH2)p-COOR51(ここでpは0、1または2でありそしてR51はHまた は炭素原子1〜4個を有するアルキル基である)を示し; nは0、1、2、3または4であり; Bは式IVa、IVb、IVcまたはIVd で表される構造断片を示し、ここで上記式中、 rは0または1であり; X1はCH2またはNHを示すかまたは存在しない; X2はCH2、NHまたはC=NHを示し; X3はNH、C=NH、N-C(NH)-NH2、CH-C(NH)-NH2、CH-NH-C(NH)-NH2またはCH-CH2 -C(NH)-NH2-を示し; X4はCH2またはNHを示し; X5はC(NH)-NH2またはNH-C(NH)-NH2を示し; X6はCHまたはNを示し; R6はHまたは炭素原子1〜4個を有するアルキル基である〕で表される化合 物もしくはその立体異性体またはその生理学的に許容しうる塩。 2.一般式 A1-A2-NH-(CH2)n-B-D 式V 〔式中、 A1は式IIa、IIb、IIc、IIdまたはIIe で表される構造断片を示し、上記式中、 kは0、1、2、3または4であり; mは1、2、3または4であり; qは0、1、2または3であり; R1はR11OOC−アルキル−(ここでアルキル基は炭素原子1〜4個を有し、カ ルボニル基に対してα位に置換されることもあり、そのα置換基は基R17-(CH2)p -であり、ここでpは0、1または2でありそしてR17はCOOR12、CONHR12であり 、ここでR12はHまたは炭素原子1〜4個を有するアルキル基またはベンジル基 であり、そしてR11はHまたは炭素原子1〜6個を有するアルキル基またはベン ジル基である)を示し、または R1はPh(4-COOR12)-CH2-(ここでR12は前述の定義を有する)を示し、または R1はR13-NH-CO−アルキル−(ここでアルキル基は炭素原子1〜 4個を有し、カルボニルに対してα位に炭素原子1〜4個を有するアルキル基で 置換されることもあり、そしてR13はH、炭素原子1〜4個を有するアルキル基 または-CH2COOR12であり、ここでR12は前述の定義を有する)を示し、または R1はR12OOC-CH2-OOC−アルキル−(ここでアルキル基は1〜4個の炭素原子 を有し、カルボニルに対してα位に炭素原子1〜4個を有するアルキル基で置換 されることもあり、そしてR12は前述の定義を有する)を示し、または R1はR14SO2-、Ph(4-COOR12)-SO2-、Ph(3-COOR12)-SO2-、Ph(2-COOR12)-SO2- (ここでR12は前述の定義を有しそしてR14は炭素原子1〜4個を有するアルキル 基である)を示し、または R1は-CO-R15(ここでR15は炭素原子1〜4個を有するアルキル基である)を 示し、または R1は-CO-OR15(ここでR15は前述の定義を有する)を示し、または R1は-CO-(CH2)p-COOR12(ここでR12は前述の定義を有しそしてpは0、1ま たは2である)を示し、または R2はH、炭素原子1〜4個を有するアルキル基またはR21OOC−アルキル−( ここでアルキル基は炭素原子1〜4個を有し、R21はHまたは炭素原子1〜4個 を有するアルキル基またはベンジル基である)を示し; R3は炭素原子1〜4個を有するアルキル基(このアルキル基は1個以上のフ ッ素原子を担持することもある)を示し、または R3はシクロペンチル、シクロヘキシルまたはフェニル基(これらは炭素原子 1〜4個を有するアルキル基で置換されることもあ る)を示し、または R3はOR31基(ここでR31はHまたは炭素原子1〜4個を有するアルキル基で ある)で置換されたフェニル基を示しそしてkは0または1であり、または R3は1−ナフチルまたは2−ナフチル基を示しそしてkは0または1であり 、または R3はシス−またはトランス−デカリン基を示しそしてkは0または1であり 、または R3は4−ピリジル、3−ピロリジルまたは3−インドリル(これらはOR31基 で置換されることもあり、ここでR31は前述の定義を有する)を示しそしてkは 0または1であり、または R3はSi(Me)3またはCH(R32)2(ここでR32はシクロヘキシルまたはフェニル基 である)を示し; R4はH、炭素原子1〜4個を有するアルキル基、シクロヘキシルまたはフェ ニル基を示し; A2は式IIIa、IIIbまたはIIIc で表される構造断片を示し、ここで上記式中、 pはお、1または2であり; mは1、2、3または4であり; Yはメチレン基を示し:または Yはエチレン基を示しそして得られる5員環は1個以上のフッ素原子、1個 のヒドロキシル基または1個のオキソ基を4−位に担持していることもありまた は不飽和であることもあり、または Yは4−位にヘテロ原子官能性を有して、-CH2-O-、-CH2-S-、CH2-SO-を示 し、または Yはn−プロピレン基を示しそして得られる6員環は1個のフッ素原子、1 個のヒドロキシル基または1個のオキソ基を5−位に、2個のフッ素原子を4− または5−位の一方に担持していることもありまたは4−および5−位が不飽和 であることもあり、または炭素原子1〜4個を有するアルキル基を4−位に担持 していることもあり、または Yは-CH2-O-CH2-、-CH2-S-CH2-、CH2-SO-CH2-を示し、または Yは-CH2-CH2-CH2-CH2-を示し; R3は前述の定義を有し; R5はHまたは炭素原子1〜4個を有するアルキル基を示し、または R5は-(CH2)p-COOR51(ここでpは0、1または2でありそしてR51はHまた は炭素原子1〜4個を有するアルキル基である)を示し; nは0、1、2、3または4であり; Bは式IVa、IVb、IVcまたはIVd で表される構造断片を示し、ここで上記式中、 rは0または1であり; X1はCH2またはNHを示すかまたは存在しない; X2はCH2、NHまたはC=NHを示し; X3はNH、C=NH、N-C(NH)-NH2、CH-C(NH)-NH2、CH-NH-C(NH)-NH2またはCH-CH2 -C(NH)-NH2-を示し; X4はCH2またはNHを示し; X5はC(NH)-NH2またはNH-C(NH)-NH2を示し; X6はCHまたはNを示し; R6はHまたは炭素原子1〜4個を有するアルキル基であり; DはZまたは(Z)2であり; Zはベンジルオキシカルボニル基である〕で表される化合物もしくはその立 体異性体またはその生理学的に許容しうる塩。 3.A1が式IIaまたはIIbの構造断片である請求項1または2記載の化合物。 4.R1がR11OOC−アルキル−(ここでアルキル基は炭素原子1〜4個を有しそし てR11はHである)を示す請求項1〜3のいずれか1項に記載の化合物。 5.A2が式IIIaの構造断片である請求項1〜4のいずれか1項に記載の化合物 。 6.A2が式IIIbの構造断片である請求項1〜4のいずれか1項に記載の化合物 。 7.Bが式IVa(ここでX1、X2およびX4はCH2であり、X3はCH-C(NH)-NH2であり 、rは1でありそしてnは1である)の構造断片である請求項1〜6のいずれか 1項に記載の化合物。 8.Bが式IVa(ここでX1、X2およびX4はCH2であり、X3はN-C(NH)-NH2であり、 rは0または1でありそしてnは1または2である)の構造断片である請求項1 〜6のいずれか1項に記載の化合物。 9.Bが式IVb(ここでX5はC(NH)-NH2であり、R6はHでありそしてnは1であ る)の構造断片である請求項1〜6のいずれか1項に記載の化合物。 10.Bが式IVa(ここでX1およびX3はNHであり、X2はC=NHであり、X4はCH2であ り、rは1でありそしてnは2である)の構造断片である請求項1〜6のいずれ か1項に記載の化合物。 11.Bが式IVa(ここでX1は存在せず、X2およびX4はCH2であり、X3はN-C(NH)-N H2であり、rは0でありそしてnは1または2である)の構造断片である請求項 1〜6のいずれか1項に記載の化合物。 12.nが1または2であり、A1が式IIa〔ここでkは0または1であり、R1はR1 1 OOC−アルキル−(ここでアルキル基は炭素原子1〜4個を有する)を示し、R2 はHを示し、R3はシクロヘキシル基を示す〕の構造断片であり、A2が式IIIa〔 ここでYはメチレン基、エチレン基またはn−プロピレン基を示しそして得られ る6員環は炭素原子1〜4個を有するアルキル基を4−位に担持することもあり 、R5はHを示す〕の構造断片を示し、Bが式IVa〔ここで X1、X2およびX4はCH2であり、X3はCH-C(NH)-NH2またはN-C(NH)-NH2であり、rは 0または1であるか、またはX1およびX3はNHであり、X2はC=NHであり、X4はCH2 であり、rは1であるか、またはX1は存在せず、X2およびX4はCH2であり、X3はN -C(NH)-NH2であり、rは0である〕の構造断片を示す請求項1または2記載の化 合物。 13.nが1であり、Alが式IIa〔ここでkは0または1であり、R1はR11OOC−ア ルキル−(ここでアルキル基は炭素原子1〜4個を有する)を示し、R2はHを示 し、R3はシクロヘキシル基を示す〕の構造断片であり、A2が式IIIa〔ここでY はメチレン基、エチレン基またはn−プロピレン基を示しそして得られる6員環 は炭素原子1〜4個を有するアルキル基を4−位に担持することもあり、R5はH を示す〕の構造断片を示し、Bが式IVb〔ここでX5はC(NH)-NH2でありそしてR6 はHである〕の構造断片を示す請求項1または2記載の化合物。 14.HOOC-CH2-(R)Cgl-Aze-Pab HOOC-CH2-CH2-(R)Cgl-Aze-Pab HOOC-CH2-(R)Cgl-Pro-Pab HOOC-CH2-CH2-(R)Cgl-Pro-Pab (HOOC-CH2)2-(R)Cgl-Pro-Pab H-(R)Cgl-Pic-Pab HOOC-CH2-(R,S)CH(COOH)-(R)Cgl-Pic-Pab H-(R)Cha-Aze-Pab HOOC-CH2-(R)Cha-Aze-Pab HOOC-CH2-(R,S)CH(COOH)-(R)Cha-Aze-Pab HOOC-CH2-(R又はS)CH(COOH)-(R)Cha-Aze-Pab/a HOOC-CH2-(R又はS)CH(COOH)-(R)Cha-Aze-Pab/b HOOC-CH2-CH2-(R)Cha-Aze-Pab HOOC-CH2-NH-CO-CH2-(R)Cha-Aze-Pab H-(R)Cha-Pro-Pab HOOC-CH2-(R)Cha-Pro-Pab HOOC-CH2-(Me)(R)Cha-Pro-Pab HOOC-CH2-CH2-(R)Cha-Pro-Pab HOOC-CH2-CH2-(Me)(R)Cha-Pro-Pab HOOC-CH2-(R又はS)CH(COOH)-(R)Cha-Pro-Pab/a HOOC-CH2-(R又はS)CH(COOH)-(R)Cha-Pro-Pab/b HOOC-CH2-NH-CO-CH2-(R)Cha-Pro-Pab EtOOC-CH2-CH2-CH2-(R)Cha-Pro-Pab Ph(4-COOH)-SO2-(R)Cha-Pro-Pab H-(R)Cha-Pic-Pab HOOC-CH2-(R)Cha-Pic-Pab HOOC-CH2-(R又はS)CH(COOH)-(R)Cha-Pic-Pab/a HOOC-CH2-(R又はS)CH(COOH)-(R)Cha-Pic-Pab/b HOOC-CH2-CH2-(R)Cha-Pic-Pab HOOC-CO-(R)Cha-Pic-Pab HOOC-CH2-CO-(R)Cha-Pic-Pab Me-OOC-CH2-CO-(R)Cha-Pic-Pab H2N-CO-CH2-(R)Cha-Pic-Pab Boc-(R)Cha-Pic-Pab Ac-(R)Cha-Pic-Pab Me-SO2-(R)Cha-Pic-Pab H-(R)Cha-(R,S)βPic-Pab HOOC-CH2-CH2-(R)Cha-(R,S)βPic-Pab HOOC-CH2-(R)Cha-Val-Pab HOOC-CH2-CH2-(R)Cha-Val-Pab H-(R)Hoc-Aze-Pab HOOC-CH2-CH2-(R)Hoc-Aze-Pab HOOC-CH2-(R,S)CH(COOH)-(R)Hoc-Pro-Pab HOOC-CH2-(R)Hoc-Pic-Pab (HOOC-CH2)2-(R)Hoc-Pic-Pab HOOC-CH2-(R)Pro(3-(S)Ph)-Pro-Pab HOOC-CH2-CH2-(R)Pro(3-(S)Ph)-Pro-Pab HOOC-CH2-CH2-(R)Tic-Pro-Pab HOOC-CH2-CH2-(R)Cgl-Aze-Pig HOOC-CH2-(R)Cgl-Pro-Pig H-(R)Cha-Aze-Pig HOOC-CH2-(R)Cgl-Aze-Pac H-(R)Cha-Pro-Pac H-(R)Cgl-Ile-Pab H-(R)Cgl-Aze-Pab HOOC-(R,S)CH(Me)-(R)Cha-Pro-Pab MeOOC-CH2-(R)Cgl-Aze-Pab EtOOC-CH2-(R)Cgl-Aze-Pab nBuOOC-CH2-(R)Cgl-Aze-Pab nHexOOC-CH2-(R)Cgl-Aze-Pab H-(R)Cgl-Pro-Pac HOOC-CH2-(R)Cha-Pro-Pac HOOC-CH2-CH2-(R)Cgl-Pro-Pac HOOC-CH2-CH2-(R)Cha-Aze-Pac HOOC-CH2-(R)Cha-Aze-Pig HOOC-CH2-(R)Cha-Pro-Pig HOOC-CH2-CH2-(R)Cha-Pro-Pig (HOOC-CH2)2-(R)Cgl-Pro-Pig HOOC-CH2-CH2(HOOC-CH2)-(R)Cha-Pro-Pig HOOC-CH2-(R)Cgl-Aze-(R,S)Itp HOOC-CH2-(R)Cha-Aze-(R,S)Itp H-(R)Cha-Pic-(R,S)Itp HOOC-CH2-(R)Cha-Pic-(R,S)Itp H-(R)Cgl-Pro-(R,S)Hig HOOC-CH2-(R)Cgl-Pro-(R,S)Hig H-(R)Cha-Pro-(R,S)Hig H-(R)Cgl-Aze-Rig HOOC-CH2-(R)Cgl-Aze-Rig HOOC-CH2-(R)Cha-Pro-Rig HOOC-CH2-CH2-(R)Cha-Aze-Rig HOOC-CH2-(R)Cha-Pro-(S)Itp H-(R)Cha-Pro-(R,S)Nig H-(R)Cha-Pro-Mig H-(R)Cha-Pro-Dig H-(R)Cha-Aze-Dig から選択される化合物もしくはその立体異性体またはその生理学的に許容しう る塩。 15.HOOC-CH2-(R)Cgl-Aze-Pab HOOC-CH2-CH2-(R)Cha-Aze-Pab HOOC-CH2-(R)Cha-Pro-Pab HOOC-CH2-CH2-(R)Cha-Pro-Pab HOOC-CH2-(R)Cha-Pic-Pab HOOC-CH2-(R)Cgl-Pro-Pig EtOOC-CH2-(R)Cgl-Aze-Pab HOOC-CH2-(R)Cha-Pro-Pac HOOC-CH2-(R)Cha-Pro-Pig から選択される化合物もしくはその立体異性体またはその生理学的に許容しう る塩。 16.BnOOC-CH2-(R)Cgl-Aze-Pab(Z) BnOOC-CH2-CH2-(R)Cgl-Aze-Pab(Z) BnOOC-CH2-(R)Cgl-Pro-Pab(Z) BnOOC-CH2-CH2-(R)Cgl-Pro-Pab(Z) (BnOOC-CH2)2-(R)Cgl-Pro-Pab(Z) BnOOC-CH2-(R,S)CH(COOBn)-(R)Cgl-Pic-Pab(Z) BnOOC-CH2-(R)Cha-Aze-Pab(Z) BnOOC-CH2-(R,S)CH(COOBn)-(R)Cha-Aze-Pab(Z) BnOOC-CH2-(R又はS)CH(COOBn)-(R)Cha-Aze-Pab(Z)/a BnOOC-CH2-(R又はS)CH(COOBn)-(R)Cha-Aze-Pab(Z)/b BnOOC-CH2-CH2-(R)Cha-Aze-Pab(Z) BnOOC-CH2-NH-CO-CH2-(R)Cha-Aze-Pab(Z) BnOOC-CH2-(R)Cha-Pro-Pab(Z) BnOOC-CH2-(Me)(R)Cha-Pro-Pab(Z) BnOOC-CH2-CH2-(R)Cha-Pro-Pab(Z) BnOOC-CH2-CH2-(Me)(R)Cha-Pro-Pab(Z) BnOOC-CH2-(R,S)CH(COOBn)-(R)Cha-Pro-Pab(Z) BnOOC-CH2-NH-CO-CH2-(R)Cha-Pro-Pab(Z) Ph(4-COOH)-SO2-(R)Cha-Pro-Pab(Z) Boc-(R)Cha-Pic-Pab(Z) BnOOC-CH2-(R)Cha-Pic-Pab(Z) BnOOC-CH2-(R,S)CH(COOBn)-(R)Cha-Pic-Pab(Z) BnOOC-CH2-CH2-(R)Cha-Pic-Pab(Z) EtOOC-CO-(R)Cha-Pic-Pab(Z) MeOOC-CH2-CO-(R)Cha-Pic-Pab(Z) H2N-CO-CH2-(R)Cha-Pic-Pab(Z) Ac-(R)Cha-Pic-Pab(Z) Me-SO2-(R)Cha-Pic-Pab(Z) BnOOC-CH2-(R)Cha-Val-Pab(Z) BnOOC-CH2-CH2-(R)Cha-(R,S)Val-Pab(Z) BnOOC-CH2-CH2-(R)Hoc-Aze-Pab(Z) BnOOC-CH2-(R,S)CH(COOBn)-(R)Hoc-Pro-Pab(Z) BnOOC-CH2-(R)Hoc-Pic-Pab(Z) (BnOOC-CH2)2-(R)Hoc-Pic-Pab(Z) BnOOC-CH2-(R)Pro(3-(S)Ph)-Pro-Pab(Z) BnOOC-CH2-CH2-(R)Pro(3-(S)Ph)-Pro-Pab(Z) BnOOC-CH2-CH2-(R)Tic-Pro-Pab(Z) BnOOC-CH2-CH2-(R)Cgl-Aze-Pig(Z)2 BnOOC-CH2-(R)Cgl-Pro-Pig(Z)2 BnOOC-CH2-(R)Cgl-Aze-Pac(Z) BnOOC-(R,S)CH(Me)-(R)Cha-Pro-Pab(Z) MeOOC-CH2-(R)Cgl-Aze-Pab(Z) EtOOC-CH2-(R)Cgl-Aze-Pab(Z) nBuOOC-CH2-(R)Cgl-Aze-Pab(Z) nHexOOC-CH2-(R)Cgl-Aze-Pab(Z) BnOOC-CH2-(R)Cha-Pro-Pac(Z) BnOOC-CH2-CH2-(R)Cgl-Pro-Pac(Z) BnOOC-CH2-CH2-(R)Cha-Aze-Pac(Z) BnOOC-CH2-(R)Cha-Aze-Pig(Z) BnOOC-CH2-(R)Cha-Pro-Pig(Z) BnOOC-CH2-CH2-(R)Cha-Pro-Pig(Z) (BnOOC-CH2)2-(R)Cgl-Pro-Pig(Z) BnOOC-CH2-CH2(BnOOC-CH2)-(R)Cha-Pro-Pig(Z) BnOOC-CH2-(R)Cha-Pic-(R,S)Itp(Z) BnOOC-CH2-(R)Cgl-Pro-(R,S)Hig(Z) BnOOC-CH2-(R)Cgl-Aze-Rig(Z) BnOOC-CH2-(R)Cha-Pro-Rig(Z) BnOOC-CH2-CH2-(R)Cha-Aze-Rig(Z) から選択される化合物もしくはその立体異性体またはその生理学的に許容しう る塩。 17.BnOOC-CH2-(R)Cgl-Aze-Pab(Z) BnOOC-CH2-(R)Cha-Pro-Pab(Z) BnOOC-CH2-(R)Cha-Pic-Pab(Z) BnOOC-CH2-(R)Cgl-Pro-Pig(Z)2 EtOOC-CH2-(R)Cgl-Aze-Pab(Z) BnOOC-CH2-(R)Cha-Pro-Pac(Z) BnOOC-CH2-(R)Cha-Pro-Pig(Z) から選択される化合物もしくはその立体異性体またはその生理学的に許容しう る塩。 18.H-(R)Pro-Phe-Pab HOOC-CH2-(R)Pro-Phe-Pab H-(R)Phe-Phe-Pab HOOC-CH2-(R)Phe-Phe-Pab HOOC-CO-(R)Phe-Phe-Pab から選択される化合物もしくはその立体異性体またはその生理学的に許容しう る塩。 19.Boc-(R)Pro-Phe-Pab(Z) BnOOC-CH2-(R)Pro-Phe-Pab(Z) Boc-(R)Phe-Phe-Pab(Z) MeOOC-CO-(R)Phe-Phe-Pab(Z) BnOOC-CH2-(R)Phe-Phe-Pab(Z) から選択される化合物もしくはその立体異性体またはその生理学的に許容しう る塩。 20.N−末端アミノ酸を用いる場合には後に標準手法で第2アミノ酸が加えられ るが、N−末端保護されたアミノ酸またはジペプチドまたはアミノ酸を下記化合 物 H2N-(CH2)n-X (式中、nは0、1、2、3または4であり、XはBまたはB-Dであり、ここ でBは式Iに記載の定義を有しそしてDは式Vに記載の定義を有する)それ自体 またはそのグアニジノ窒素またはアミジノ窒素がアミン保護基例えばベンジルオ キシカルボニル基またはtert−ブチルオキシカルボニル基またはp−トルエンス ルホニル基でモノまたはジ保護されている該化合物またはXがBに変換されうる 基である該化合物に結合させ、次いで保護基を除去するかまたはN−末端窒素の 脱保護およびそれに続くN−末端窒素のアルキル化を行い、所望により知られた 方法で脱保護し、所望により生理学的に許容しうる塩を形成させそして反応が立 体異性体混合物を生成する場合にはそれらを標準クロマトグラフィーまたは再結 晶法で場合により分割し、所望により単一の立体異性体を単離することからなる 請求項1〜19のいずれか1項に記載の化合物の製造方法。 21.請求項1〜19のいずれか1項に記載の化合物を製造するにあたり、 a)(方法Ia)式IまたはV中のA1およびA2から選択されるN−末端保護さ れたジペプチドを標準的なペプチド結合を用いて下記式 〔式中nは式Iに記載の定義を有し、W1はN−末端アミノ保護基 例えばtert−ブチルオキシカルボニルおよびベンジルオキシカルボニルでありそ してQ1は-C(NH)-NH2、-C(NW2)-NH-W2、-C(NH)-NH-W2、-NH-C(NH)-NH2、-NH-C(NH )-NH-W2、-N(W2)-C(NH)-NH-W2または-NH-C(NW2)-NH-W2(ここでW2はアミノ保護 基例えばtert−ブチルオキシカルボニルまたはベンジルオキシカルボニルである )であり、またはQ1は-CN、-CO-NH2または-CS-NH2であって、ここで該基はその 後アミジノ基に変換され、またはQ1はNH2またはNH-W2(ここでW2は前述の定義を 有する)であって、ここでQ1が-NH-W2(この場合のW2はW1に垂直でなければなら ない)の場合には本技術分野で知られた方法によってW2−基の脱保護を行った後 にそのアミノ基はグアニジノ基(Q1=-NH-C(NH)-NH2が得られる)に変換される〕 に示されるように結合させる; b)(方法Ib)式IまたはV中のA2から選択されるN−末端保護されたアミ ノ酸を標準的なペプチド結合を用いて下記式 〔式中n、W1およびQ1は前述の定義を有する)に示されるように結合させ、次 いでW1−基の脱保護を行いそして保護された形態のN−末端アミノ酸と結合させ て前記方法Iaに記載の保護されたペプチドを得る; c)(方法IIa)式IまたはV中のA1およびA2から選択されたN−末端保護さ れたジペプチドを標準的なペプチド結合を用いて下 記式 〔式中nは式Iに記載の定義を有し、W1はN−末端アミノ保護基例えばtert− ブチルオキシカルボニルおよびベンジルオキシカルボニルでありそしてQ1は-C(N H)-NH2、-C(NW2)-NH-W2、-C(NH)-NH-W2、-NH-C(NH)-NH2、-NH-C(NH)-NH-W2、-N( W2)-C(NH)-NH-W2または-NH-C(NW2)-NH-W2(ここでW2はアミノ保護基例えばtert −ブチルオキシカルボニルまたはベンジルオキシカルボニルである)であり、ま たはQ1は-CN、-CO-NH2またはCS-NH2であって、ここで該基はその後アミジノ基に 変換され、またはQ1はNH2またはNH-W2(ここでW2は前述の定義を有する)であっ て、ここでQ1が-NH-W2(この場合のW2はW1に垂直でなければならない)の場合に は本技術分野で知られた方法によってW2−基の脱保護を行った後にそのアミノ基 は引続きグアニジノ基(Q1=-NH-C(NH)-NH2が得られる)に変換される〕に示さ れるように結合させる; d)(方法IIb)式IまたはV中のA2から選択されるN−末端保護されたアミ ノ酸を標準的なペプチド結合を用いて、下記式 〔式中n、W1およびQ1は前述の定義を有する)に示されるように結合させ、次 いでW1−基の脱保護を行いそして保護された形態のN−末端アミノ酸と結合させ て前記方法IIaに記載の保護されたペプチドを得る; e)(方法IIIa)式IまたはV中のA1およびA2から選択されるN−末端保護さ れたジペプチドを標準的なペプチド結合を用いて下記式 〔式中nは式Iに記載の定義を有し、そしてX1、X2およびX4がCH2である場合 にはrは0または1でありまたはX2およびX4がCH2でありそしてX1が存在しない 場合にはrは0であり、W1はN−末端アミノ保護基例えばtert−ブチルオキシカ ルボニルおよびベンジルオキシカルボニルでありそしてQ2は-C(NH)-NH2、-C(NW2 )-NH-W2または-C(NH)-NH-W2(ここでW2はアミノ保護基例えばtert−ブチルオキ シカルボニルまたはベンジルオキシカルボニルである) であるかまたはQ2はW2と同じであり、そこでW2基(この場合W2はW1に垂直でなけ ればならない)の脱保護後そのアミノ基は引続き本技術分野で知られた方法によ り保護されていないかN−保護されたかまたはN,N'−ジ保護されたグアニジン化 試薬を使用してグアニジノ基に変換される〕に示されるように結合させる; f)(方法IIIb)式IまたはV中のA2から選択されるN−末端保護されたアミ ノ酸を標準的なペプチド結合を用いて下記式 〔式中n、r、X1、X2およびX4、W1およびQ2は前述の定義を有する)に示され るように結合させ、次いでW1−基の脱保護を行いそして保護された形態のN−末 端アミノ酸と結合させて前記方法IIIaに記載の保護されたペプチドを得る; g)(方法IVa)式IまたはV中のA1およびA2から選択されるN−末端保護さ れたジペプチドを標準的なペプチド結合を用いて下記式 〔式中nは式Iに記載の定義を有し、W1はN−末端アミノ保護基例えばtert− ブチルオキシカルボニルまたはベンジルオキシカルボニルでありそしてW3はHま たはアミノ保護基例えばアリールスルホニル、ベンジルオキシカルボニルまたは tert−ブチルオキシカルボニルである)に示されるように結合させる; h)(方法IVb)式IまたはV中のA2から選択されるN−末端保護されたアミ ノ酸を標準的なペプチド結合を用いて下記式 〔式中n、W1およびW3は前述の定義を有する)に示されるように結合させ、次 いでW1−基の脱保護を行いそして保護された形態のN−末端アミノ酸と結合させ て前記方法IVaに記載の保護されたペプチドを得る; ことからなり、最終化合物は使用するQ1基またはQ2基の性質により任意の以下 の方法: 保護基の除去(Q1=-C(NH)-NH2、-C(NW2)-NH-W2、-C(NH)-NH-W2、-NH-C(NH)- NH2、-NH-C(NH)-NH-W2、-N(W2)-C(NH)-NH-W2または-NH-C(NW2)-NH-W2である場合 ); または W1−基の選択的脱保護〔例えばQ1またはQ2=-C(NW2)-NH-W2、-C(NH)-NH-W2 、-NH-C(NH)-NH-W2、-N(W2)-C(NH)-NH-W2または-NH-C(NW2)-NH-W2(この場合のW2 はW1に垂直でなければならない)である場合〕およびそれに続くN−末端窒素 のアルキル化および所望による脱保護; を用いて製造することができる上記の製造方法。 22.治療に使用する請求項1〜19項のいずれか1項に記載の化合物。 23.抗凝固または抗血栓剤として使用する請求項1〜5または7〜17のいずれか 1項に記載の化合物。 24.抗炎症剤として使用する請求項1〜4、6〜10または18〜19のいずれか1項 に記載の化合物。 25.請求項1〜19に記載の化合物の有効量を1種以上の製薬担体と一緒に含有す る医薬製剤。 26.請求項1〜5または7〜17のいずれか1項に記載の化合物の有効量を1種以 上の製薬担体と一緒に含有する、抗凝固または抗血栓剤用の医薬製剤。 27.請求項1〜4、6〜10または18〜19のいずれか1項に記載の化合物の有効量 を1種以上の製薬担体と一緒に含有する抗炎症剤用の医薬製剤。 28.ヒトまたは動物におけるトロンビン阻害製剤を製造するための 活性成分としての請求項1〜5または7〜17のいずれか1項に記載の化合物の使 用。 29.ヒトまたは動物におけるキニノゲナーゼ阻害製剤を製造するための活性成分 としての請求項1〜4、6〜10または18〜19のいずれか1項に記載の化合物の使 用。 30.トロンビン阻害を必要とするヒトまたは動物に請求項1〜5または7〜17の いずれか1項に記載の化合物の有効阻害量を投与することからなるトロンビン阻 害の獲得方法。 31.キノゲナーゼ阻害を必要とするヒトまたは動物に請求項1〜4、6〜10また は18〜19のいずれか1項に記載の化合物の有効阻害量を投与することからなるキ ニノゲナーゼ阻害の獲得方法。 32.ペプチドのセリンプロテアーゼ阻害剤の合成特にペプチドのトロンビン阻害 剤またはペプチドのキニノゲナーゼ阻害剤の合成における出発物質としての、式 で表される化合物それ自体もしくは窒素がモノ−またはジ保護されたアミジノ 基を有する該化合物またはその塩の使用。 33.医薬的に活性な化合物特にペプチド化合物中の構造エレメントとしての式 で表される構造断片。 34.4−アミノメチル−1−(N−ベンジルオキシカルボニルアミジノ)ベンゼ ンの化合物それ自体、その塩または他の窒素がベンジルオキシカルボニル基で保 護されている該化合物。 35.トロンビン阻害剤の合成特にペプチドトロンビン阻害剤の合成における出発 物質としての式 で表される化合物それ自体もしくは窒素が保護基でモノ−またはジ保護されて いるアミジノ基を有する該化合物またはその塩の使用。 36.トロンビン阻害剤特にペプチドトロンビン阻害剤中の構造エレメントとして の式 で表される構造断片。 37.4−アミノメチル−1−(N−ベンジルオキシカルボニルアミジノ)シクロ ヘキサンの化合物それ自体、その塩または他の窒素がベンジルオキシカルボニル 基で保護されている該化合物。 38.式 で表される化合物それ自体もしくは窒素が保護基でモノ−または ジ保護されているアミジノ基を有する該化合物またはその塩。 39.セリンプロテアーゼ阻害剤の合成における出発物質としての請求項38に記載 の化合物の使用。 40.トロンビン阻害剤特にペプチドのトロンビン阻害剤中の構造エレメントとし ての式 で表される構造断片。 41.式 で表される化合物それ自体もしくは窒素が保護基でモノ−またはジ保護されて いるアミジノ基を有する該化合物またはその塩。 42.セリンプロテアーゼ阻害剤の合成における出発物質としての請求項41記載の 化合物の使用。 43.トロンビン阻害剤特にペプチドのトロンビン阻害剤中の構造エレメントとし ての式 で表される構造断片。 44.化合物4−アミノメチル−1−ベンジルオキシ−カルボニルアミジノピペリ ジンそれ自体、その塩または他の窒素がベンジルオ キシカルボニル基で保護されている該化合物。 45.式 (式中nは1または2でありそしてsは0または1である)で表される化合物 それ自体もしくは窒素が保護基でモノ−またはジ保護されているアミジノ基を有 する該化合物またはその塩。 46.セリンプロテアーゼ阻害剤の合成における出発物質としての請求項45記載の 化合物の使用。 47.トロンビン阻害剤特にペプチドのトロンビン阻害剤中の構造エレメントとし ての式 (式中nは1または2でありそしてsは0または1である)で表される構造断 片。 48.(3RS)−1−(N−ベンジルオキシカルボニルアミジノ)−3−アミノメチ ルピロリジン、(3RS)−1−(N−ベンジルオキシカルボニル−アミジノ)−3 −アミノエチルピロリジン、3−アミノメチル−1−(N−ベンジルオキシカル ボニル−アミジノ)アゼチジンまたは3−アミノエチル−1−(N−ベンジルオ キシカル ボニル−アミジノ)アゼチジンである化合物それ自体、その塩または他の窒素が ベンジルオキシカルボニル基で保護されている該化合物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9301916-4 | 1993-06-03 | ||
SE19939301916A SE9301916D0 (sv) | 1993-06-03 | 1993-06-03 | New peptides derivatives |
PCT/SE1994/000535 WO1994029336A1 (en) | 1993-06-03 | 1994-06-02 | New peptide derivatives |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2001091958A Division JP2001322974A (ja) | 1993-06-03 | 2001-03-28 | 4−アミノメチル−1−アミジノベンゼン化合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH08511018A true JPH08511018A (ja) | 1996-11-19 |
JP3205558B2 JP3205558B2 (ja) | 2001-09-04 |
Family
ID=20390165
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50166595A Expired - Fee Related JP3205558B2 (ja) | 1993-06-03 | 1994-06-02 | 新規ペプチド誘導体 |
JP2001091958A Pending JP2001322974A (ja) | 1993-06-03 | 2001-03-28 | 4−アミノメチル−1−アミジノベンゼン化合物 |
JP2001158596A Pending JP2002047264A (ja) | 1993-06-03 | 2001-05-28 | アミノアルキルベンゼン化合物 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2001091958A Pending JP2001322974A (ja) | 1993-06-03 | 2001-03-28 | 4−アミノメチル−1−アミジノベンゼン化合物 |
JP2001158596A Pending JP2002047264A (ja) | 1993-06-03 | 2001-05-28 | アミノアルキルベンゼン化合物 |
Country Status (40)
Country | Link |
---|---|
US (4) | US5602253A (ja) |
EP (2) | EP1067136A1 (ja) |
JP (3) | JP3205558B2 (ja) |
KR (1) | KR100339456B1 (ja) |
CN (2) | CN1099425C (ja) |
AT (1) | ATE200783T1 (ja) |
BR (1) | BR9406746A (ja) |
CA (1) | CA2162900C (ja) |
CZ (1) | CZ290104B6 (ja) |
DE (3) | DE122004000045I2 (ja) |
DK (1) | DK0701568T3 (ja) |
EE (1) | EE03264B1 (ja) |
EG (1) | EG20671A (ja) |
ES (1) | ES2128277T3 (ja) |
FI (1) | FI119812B (ja) |
GR (1) | GR3036258T3 (ja) |
HK (1) | HK1031375A1 (ja) |
HR (1) | HRP940311B1 (ja) |
HU (2) | HU0103039D0 (ja) |
IL (2) | IL109634A (ja) |
IS (1) | IS1805B (ja) |
LT (1) | LT3768B (ja) |
LU (1) | LU91173I2 (ja) |
MX (1) | MX9404114A (ja) |
MY (1) | MY119155A (ja) |
NL (1) | NL300178I2 (ja) |
NO (2) | NO314406B1 (ja) |
NZ (1) | NZ267534A (ja) |
PL (1) | PL181968B1 (ja) |
PT (1) | PT701568E (ja) |
RS (1) | RS49576B (ja) |
RU (1) | RU2142469C1 (ja) |
SA (1) | SA94150051B1 (ja) |
SE (1) | SE9301916D0 (ja) |
SG (1) | SG48013A1 (ja) |
SI (1) | SI0701568T1 (ja) |
SK (1) | SK283150B6 (ja) |
TW (1) | TW403731B (ja) |
UA (1) | UA65518C2 (ja) |
WO (1) | WO1994029336A1 (ja) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002532467A (ja) * | 1998-12-14 | 2002-10-02 | アストラゼネカ アクチボラグ | 新規アミジノ誘導体およびトロンビン阻害剤としてのそれらの使用 |
JP2002543148A (ja) * | 1999-05-03 | 2002-12-17 | アストラゼネカ アクチボラグ | カルボキシペプチダーゼu阻害剤とトロンビン阻害剤とを含有する医薬製剤 |
JP2003503508A (ja) * | 1999-07-02 | 2003-01-28 | アストラゼネカ アクチボラグ | メラガトランの実質的結晶形 |
JP2004512376A (ja) * | 2000-11-06 | 2004-04-22 | アストラゼネカ アクチボラグ | 虚血性障害の処置用医薬品の製造のためのメラガトランの使用 |
JP2006249098A (ja) * | 1994-01-27 | 2006-09-21 | Mitsubishi Chemicals Corp | プロリンアミド誘導体 |
JP2006321807A (ja) * | 1997-06-19 | 2006-11-30 | Astrazeneca Ab | 新規なアミジノ誘導体およびトロンビン阻害剤としてのその使用 |
JP2007039472A (ja) * | 1998-09-03 | 2007-02-15 | Astrazeneca Ab | 速放性錠剤 |
JP2007536197A (ja) * | 2003-06-25 | 2007-12-13 | アストラゼネカ アクチボラグ | メラガトランの新規製造法 |
JP2011519845A (ja) * | 2008-04-29 | 2011-07-14 | ヴァンティア リミテッド | アミノピリジン誘導体 |
Families Citing this family (116)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5583146A (en) * | 1992-12-02 | 1996-12-10 | Bristol-Myers Squibb Company | Heterocyclic thrombin inhibitors |
US6984627B1 (en) * | 1993-06-03 | 2006-01-10 | Astrazeneca Ab | Peptide derivatives |
SE9900043D0 (sv) * | 1999-01-11 | 1999-01-11 | Astra Ab | New use |
SE9301916D0 (sv) * | 1993-06-03 | 1993-06-03 | Ab Astra | New peptides derivatives |
JPH09504028A (ja) * | 1993-10-21 | 1997-04-22 | ジー.ディー.サール アンド カンパニー | 酸化窒素シンターゼ抑制剤として有用なアミジノ誘導体 |
US5726159A (en) * | 1994-03-04 | 1998-03-10 | Eli Lilly And Company | Antithrombotic agents |
US5707966A (en) * | 1994-03-04 | 1998-01-13 | Eli Lilly And Company | Antithrombotic agents |
US5705487A (en) * | 1994-03-04 | 1998-01-06 | Eli Lilly And Company | Antithrombotic agents |
CA2143533A1 (en) * | 1994-03-04 | 1995-09-05 | Kenneth D. Kurz | Antithrombotic agents |
US5602101A (en) * | 1994-03-04 | 1997-02-11 | Eli Lilly And Company | Antithrombotic agents |
ZA951618B (en) * | 1994-03-04 | 1996-08-27 | Lilly Co Eli | Antithrombotic agents |
ZA951617B (en) | 1994-03-04 | 1997-02-27 | Lilly Co Eli | Antithrombotic agents. |
US5885967A (en) * | 1994-03-04 | 1999-03-23 | Eli Lilly And Company | Antithrombotic agents |
EP0764151A2 (en) * | 1994-06-10 | 1997-03-26 | Universitaire Instelling Antwerpen | Purification of serine protease and synthetic inhibitors thereof |
DE4421052A1 (de) | 1994-06-17 | 1995-12-21 | Basf Ag | Neue Thrombininhibitoren, ihre Herstellung und Verwendung |
SE9404196D0 (sv) * | 1994-12-02 | 1994-12-02 | Astra Ab | New antithrombotic formulation |
DE4443390A1 (de) * | 1994-12-06 | 1996-06-13 | Basf Ag | Neue dipeptidische p-Amidinobenzylamide mit N-terminalen Sulfonyl- bzw. Aminosulfonylresten |
KR19980702112A (ko) * | 1995-02-10 | 1998-07-15 | 페라 스타르크,요헨 카르크 | 트롬빈 억제제 |
MX9706069A (es) * | 1995-02-17 | 1997-10-31 | Basf Ag | Nuevos inhibidores de la trombina. |
US5710130A (en) * | 1995-02-27 | 1998-01-20 | Eli Lilly And Company | Antithrombotic agents |
US5914319A (en) * | 1995-02-27 | 1999-06-22 | Eli Lilly And Company | Antithrombotic agents |
US5629324A (en) * | 1995-04-10 | 1997-05-13 | Merck & Co., Inc. | Thrombin inhibitors |
US5610308A (en) * | 1995-05-18 | 1997-03-11 | Bristol-Myers Squibb Company | Process for preparing intermediates for thrombin inhibitors |
SA96170106A (ar) * | 1995-07-06 | 2005-12-03 | أسترا أكتيبولاج | مشتقات حامض أميني جديدة |
JP2008024720A (ja) * | 1995-07-26 | 2008-02-07 | Mitsubishi Chemicals Corp | ペニシラミンアミド誘導体 |
NZ312791A (en) * | 1995-07-26 | 1999-07-29 | Mitsubishi Chem Corp | Penicillaminamide derivatives |
TW455580B (en) * | 1995-12-09 | 2001-09-21 | Roche Diagnostics Gmbh | 3-aminoethyl-N-amidino-2,5-dihyropyrrole-derivatives having arginine mimentic properties and pharmaceutical compositions containing these compounds |
GB9526273D0 (en) * | 1995-12-21 | 1996-02-21 | Astra Ab | New prodrugs |
AR005245A1 (es) * | 1995-12-21 | 1999-04-28 | Astrazeneca Ab | Prodrogas de inhibidores de trombina, una formulación farmaceutica que las comprende, el uso de dichas prodrogas para la manufactura de un medicamento y un procedimiento para su preparacion |
SE9600216D0 (sv) * | 1996-01-18 | 1996-01-18 | Hans Arne Hansson | Styrning av läkningsprocesser |
WO1997030073A1 (en) * | 1996-02-13 | 1997-08-21 | Akzo Nobel N.V. | Serine protease inhibitors |
IL120311A (en) * | 1996-03-01 | 2001-10-31 | Akzo Nobel Nv | Serine protease inhibitors and pharmaceuticals containing them |
TW442452B (en) * | 1996-03-01 | 2001-06-23 | Akzo Nobel Nv | Serine protease inhibitors having an alkynylamino side chain |
US5811402A (en) * | 1996-03-22 | 1998-09-22 | Eli Lilly And Company | Antithrombotic diamides |
SE9602145D0 (sv) | 1996-05-31 | 1996-05-31 | Astra Ab | New improved formulation for treatment of thromboembolism |
SE9602263D0 (sv) | 1996-06-07 | 1996-06-07 | Astra Ab | New amino acid derivatives |
WO1997049404A1 (en) * | 1996-06-25 | 1997-12-31 | Eli Lilly And Company | Anticoagulant agents |
US6200967B1 (en) | 1996-06-25 | 2001-03-13 | Eli Lilly And Company | Anticoagulant agents |
SE9602646D0 (sv) | 1996-07-04 | 1996-07-04 | Astra Ab | Pharmaceutically-useful compounds |
US6756389B2 (en) * | 1996-08-09 | 2004-06-29 | Cambridge Neuroscience, Inc. | Pharmaceutically active compounds and methods of use |
US5792761A (en) * | 1996-08-12 | 1998-08-11 | Merck & Co., Inc. | Thrombin inhibitors |
DE19632772A1 (de) | 1996-08-14 | 1998-02-19 | Basf Ag | Neue Benzamidine |
DE19632773A1 (de) * | 1996-08-14 | 1998-02-19 | Basf Ag | Neue Thrombininhibitoren |
IL121474A0 (en) * | 1996-08-23 | 1998-02-08 | Akzo Nobel Nv | Thrombin inhibitors |
SE9603724D0 (sv) * | 1996-10-11 | 1996-10-11 | Astra Ab | New pharmaceutical parenteral formulation of a thrombin inhibitor |
US5798377A (en) * | 1996-10-21 | 1998-08-25 | Merck & Co., Inc. | Thrombin inhibitors |
US5869487A (en) * | 1996-10-24 | 1999-02-09 | Merck & Co., Inc. | Pyrido 3,4-B!pyrazines for use as thrombin inhibitors |
US6740682B2 (en) | 1997-08-29 | 2004-05-25 | Tularik Limited | Meta-benzamidine derivatives as serine protease inhibitors |
AU8875798A (en) * | 1997-08-29 | 1999-03-22 | Proteus Molecular Design Ltd | Meta-benzamidine derivatives as serin protease inhibitors |
US6087373A (en) * | 1997-09-23 | 2000-07-11 | Merck & Co., Inc. | Thrombin inhibitors |
SE9704543D0 (sv) | 1997-12-05 | 1997-12-05 | Astra Ab | New compounds |
DE19755682A1 (de) * | 1997-12-15 | 1999-06-17 | Knoll Ag | Verfahren zur Ermittlung eines Dosierungschemas für Thrombininhibitoren |
JP2002501081A (ja) | 1998-01-26 | 2002-01-15 | ビーエーエスエフ アクチェンゲゼルシャフト | トロンビンインヒビター |
EP1049673A1 (de) * | 1998-01-26 | 2000-11-08 | Basf Aktiengesellschaft | Heterocyclische amidine als kallikrein protease inhibitoren |
IL139162A0 (en) | 1998-04-24 | 2001-11-25 | Dimensional Pharm Inc | Amidinohydrazone, alkoxyguanidine and aminoguanidine derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same |
SE9802938D0 (sv) | 1998-09-01 | 1998-09-01 | Astra Ab | Improved stability for injection solutions |
SE9802939D0 (sv) | 1998-09-01 | 1998-09-01 | Astra Ab | New process |
SE9802974D0 (sv) * | 1998-09-03 | 1998-09-03 | Astra Ab | New crystalline forms |
EP0987274A1 (en) * | 1998-09-15 | 2000-03-22 | Hoechst Marion Roussel Deutschland GmbH | Factor VIIa Inhibitors |
KR20000047461A (ko) * | 1998-12-29 | 2000-07-25 | 성재갑 | 트롬빈 억제제 |
TR200102037T2 (tr) | 1999-01-13 | 2001-10-22 | Astrazeneca Ab | Yeni amidinobenzilamin türevleri ve trombin engelleyiciler olarak kullanılmaları. |
SE9900070D0 (sv) | 1999-01-13 | 1999-01-13 | Astra Ab | New use |
SK14232001A3 (sk) | 1999-04-09 | 2002-06-04 | Basf Aktiengesellschaft | Nízkomolekulové inhibítory komplementárnych proteáz |
AR023510A1 (es) * | 1999-04-21 | 2002-09-04 | Astrazeneca Ab | Un equipo de partes, formulacion farmaceutica y uso de un inhibidor de trombina. |
US6239132B1 (en) | 1999-04-23 | 2001-05-29 | Merck & Co., Inc. | Thrombin inhibitors |
EP1054017B1 (de) | 1999-05-10 | 2004-10-13 | Abbott GmbH & Co. KG | Salze von Thrombininhibitoren |
EP1189618A4 (en) | 1999-06-04 | 2002-06-19 | Merck & Co Inc | thrombin |
EP1059302A1 (en) * | 1999-06-08 | 2000-12-13 | Aventis Pharma Deutschland GmbH | Factor VIIa inhibitors |
CA2383358A1 (en) * | 1999-08-31 | 2001-03-08 | Board Of Regents, The University Of Texas System | Methods and compositions of a novel serine protease inhibitor |
SE0001803D0 (sv) | 2000-05-16 | 2000-05-16 | Astrazeneca Ab | New compounds i |
DE10029015A1 (de) | 2000-06-15 | 2001-12-20 | Curacyte Ag | Hemmstoffe für den Gerinnungsfaktor Xa |
DE10029014A1 (de) | 2000-06-15 | 2001-12-20 | Univ Schiller Jena | Urokinase-Hemmstoffe |
US6433186B1 (en) | 2000-08-16 | 2002-08-13 | Astrazeneca Ab | Amidino derivatives and their use as thormbin inhibitors |
DE10049937A1 (de) * | 2000-10-06 | 2002-04-11 | Knoll Ag | Niedermolekulare Inhibitoren von Serinproteasen mit Polyhydroxyalkyl- und Polyhydroxycycloalkylresten |
WO2002044324A2 (en) | 2000-10-06 | 2002-06-06 | Xenoport, Inc. | Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs |
US7129233B2 (en) | 2000-12-01 | 2006-10-31 | Astrazeneca Ab | Mandelic acid derivatives and their use as thrombin inhibitors |
AR035216A1 (es) * | 2000-12-01 | 2004-05-05 | Astrazeneca Ab | Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios |
CA2431588A1 (en) | 2000-12-18 | 2002-06-27 | Merck & Co., Inc. | Benzylamine derivatives and their use as thrombin inhibitors |
US6528503B2 (en) | 2000-12-18 | 2003-03-04 | Merck & Co., Inc. | Thrombin inhibitors |
US7144899B2 (en) | 2001-02-09 | 2006-12-05 | Merck & Co., Inc. | Thrombin inhibitors |
DE10117730A1 (de) | 2001-04-09 | 2002-10-10 | Basf Ag | Umsetzung von (Di)Aminen in Gegenwart einer Lysinoxidase und eines Reduktionsmittels |
AR034517A1 (es) * | 2001-06-21 | 2004-02-25 | Astrazeneca Ab | Formulacion farmaceutica |
DE10133786A1 (de) * | 2001-07-16 | 2003-02-06 | Boehringer Ingelheim Pharma | Verwendung von Thrombin-Inhibitoren zur Behandlung von Arthritis |
SE0103590D0 (sv) | 2001-10-26 | 2001-10-26 | Astrazeneca Ab | New Combination |
SE0200198D0 (sv) | 2002-01-23 | 2002-01-23 | Astrazeneca Ab | New use |
ATE399175T1 (de) | 2002-03-11 | 2008-07-15 | Curacyte Ag | Hemmstoffe der urokinase, ihre herstellung und verwendung |
DE10210590A1 (de) * | 2002-03-11 | 2003-10-02 | Curacyte Ag | Hemmstoffe des Gerinnungsfaktors Xa, ihre Herstellung und Verwendung |
US7084134B2 (en) | 2002-05-02 | 2006-08-01 | Merk & Co., Inc. | Thrombin inhibitors |
EP1513553B1 (en) * | 2002-05-21 | 2008-11-19 | Mayo Foundation For Medical Education And Research | Methods and materials for treating and diagnosing kallikrein-6 related inflammatory conditions |
SE0201659D0 (sv) | 2002-05-31 | 2002-05-31 | Astrazeneca Ab | Modified release pharmaceutical formulation |
SE0201661D0 (sv) | 2002-05-31 | 2002-05-31 | Astrazeneca Ab | New salts |
DK1569912T3 (en) | 2002-12-03 | 2015-06-29 | Pharmacyclics Inc | 2- (2-hydroxybiphenyl-3-yl) -1h-benzoimidazole-5-carboxamidine derivatives as factor VIIa inhibitors. |
DE10301300B4 (de) | 2003-01-15 | 2009-07-16 | Curacyte Chemistry Gmbh | Verwendung von acylierten 4-Amidino- und 4-Guanidinobenzylaminen zur Inhibierung von Plasmakallikrein |
US7781424B2 (en) * | 2003-05-27 | 2010-08-24 | Astrazeneca Ab | Modified release pharmaceutical formulation |
DE10342108A1 (de) | 2003-09-11 | 2005-04-14 | Curacyte Chemistry Gmbh | Basisch-substituierte Benzylaminanaloga als Inhibitoren des Gerinnungsfaktors Xa, ihre Herstellung und Verwendung |
FR2867780B1 (fr) * | 2004-03-19 | 2006-05-19 | Servier Lab | Nouveaux derives de 4-oxo-4,6,7,8-tetrahydropyrrolo (1,2-a) pyrazine-6-carboxamides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
EP1736465A4 (en) | 2004-03-31 | 2009-06-17 | Ajinomoto Kk | ANILINE DERIVATIVES |
US7795205B2 (en) | 2004-04-12 | 2010-09-14 | Canyon Pharmaceuticals, Inc. | Methods for effecting regression of tumor mass and size in a metastasized pancreatic tumor |
US20060235348A1 (en) * | 2005-02-14 | 2006-10-19 | Callicoat David N | Method of extracting and analyzing the composition of bodily fluids |
JP2008540372A (ja) * | 2005-05-03 | 2008-11-20 | バイエル・クロツプサイエンス・エス・アー | 新規ヘテロシクリルエチルアミド誘導体 |
US7524354B2 (en) * | 2005-07-07 | 2009-04-28 | Research Foundation Of State University Of New York | Controlled synthesis of highly monodispersed gold nanoparticles |
WO2007103447A2 (en) * | 2006-03-06 | 2007-09-13 | Humagene, Inc. | A method for the preparation of recombinant human thrombin |
DE102006050672A1 (de) * | 2006-10-24 | 2008-04-30 | Curacyte Discovery Gmbh | Hemmstoffe des Plasmins und des Plasmakallikreins |
TW200827336A (en) | 2006-12-06 | 2008-07-01 | Astrazeneca Ab | New crystalline forms |
US20090061000A1 (en) * | 2007-08-31 | 2009-03-05 | Astrazeneca Ab | Pharmaceutical formulation use 030 |
CN102924567B (zh) * | 2008-10-28 | 2014-06-04 | 上海医药工业研究院 | 一类肽化合物、其制备方法及用途 |
TWI419700B (zh) * | 2010-01-06 | 2013-12-21 | Academia Sinica | 甘藷胰蛋白酶抑制因子用於治療發炎及痛敏感之用途 |
ES2483802T3 (es) | 2010-07-07 | 2014-08-07 | The Medicines Company (Leipzig) Gmbh | Inhibidores de serina proteasa |
CN102464701B (zh) | 2010-11-08 | 2015-10-21 | 上海医药工业研究院 | 一类新型化合物、其制备方法及用途 |
WO2012075287A2 (en) * | 2010-12-01 | 2012-06-07 | The University Of Mississippi | Novel selective inhibitors of prolylcarboxypeptidase |
DE102014108210A1 (de) | 2014-06-11 | 2015-12-17 | Dietrich Gulba | Rodentizid |
US11584714B2 (en) | 2018-05-29 | 2023-02-21 | Omeros Corporation | MASP-2 inhibitors and methods of use |
JP2021525728A (ja) * | 2018-05-29 | 2021-09-27 | オメロス コーポレーション | Masp−2阻害剤および使用方法 |
AU2020398241A1 (en) | 2019-12-04 | 2022-06-30 | Omeros Corporation | MASP-2 inhibitors and methods of use |
IL293551A (en) | 2019-12-04 | 2022-08-01 | Omeros Corp | 2-masp inhibitor compounds, preparations containing them and their uses |
EP4070658A1 (de) | 2021-04-06 | 2022-10-12 | BIORoxx GmbH | Verwendung von blutgerinnungshemmenden verbindungen als rodentizide |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2748295A1 (de) * | 1977-10-27 | 1979-05-03 | Bayer Ag | Neue derivate des bpti |
HU178398B (en) * | 1979-06-12 | 1982-04-28 | Gyogyszerkutato Intezet | Process for producing new agmatine derivatives of activity against haemagglutination |
US4568636A (en) * | 1981-03-25 | 1986-02-04 | Pentapharm Ag | Tripeptide derivatives |
US4395401A (en) * | 1981-09-09 | 1983-07-26 | Smithkline Beckman Corporation | Renally active dipeptides |
HU192646B (en) | 1984-12-21 | 1987-06-29 | Gyogyszerkutato Intezet | Process for preparing new n-alkyl-peptide aldehydes |
ZA86746B (en) | 1985-02-04 | 1986-09-24 | Merrell Dow Pharma | Novel peptidase inhibitors |
DE3505555A1 (de) * | 1985-02-18 | 1986-09-11 | Behringwerke Ag, 3550 Marburg | Neue oligopeptidylargininolderivate und deren homologe, verfahren zu deren herstellung, deren verwendung und diese enthaltende mittel |
PT84170B (pt) * | 1986-01-24 | 1989-03-30 | Sanofi Sa | Processo para a preparacao de derivados n alfa-substituidos das n alfa-aril-sulfonilaminoacil d-amidinofenil-alaninamidas |
DE3606480A1 (de) * | 1986-02-28 | 1987-09-03 | Behringwerke Ag | Oligopeptidylnitrilderivate, diese enthaltende mittel, verfahren zu ihrer herstellung und ihre verwendung |
US5187157A (en) | 1987-06-05 | 1993-02-16 | Du Pont Merck Pharmaceutical Company | Peptide boronic acid inhibitors of trypsin-like proteases |
EP0362002B1 (en) | 1988-09-01 | 1995-07-26 | Merrell Dow Pharmaceuticals Inc. | HIV protease inhibitors |
ZA897514B (en) | 1988-10-07 | 1990-06-27 | Merrell Dow Pharma | Novel peptidase inhibitors |
US5273982A (en) * | 1990-03-09 | 1993-12-28 | Hoffmann-La Roche Inc. | Acetic acid derivatives |
US5110812A (en) * | 1990-06-04 | 1992-05-05 | Bristol-Myers Squibb Co. | Azetidin-2-one derivatives as serine protease inhibitors |
US5037819A (en) * | 1990-06-04 | 1991-08-06 | Bristol-Myers Squibb Company | Azetidin-2-one derivatives as serine protease inhibitors |
TW201303B (ja) | 1990-07-05 | 1993-03-01 | Hoffmann La Roche | |
GB9017694D0 (en) * | 1990-08-13 | 1990-09-26 | Sandoz Ltd | Improvements in or relating to organic chemistry |
GB9019558D0 (en) | 1990-09-07 | 1990-10-24 | Szelke Michael | Enzyme inhibitors |
IL99538A0 (en) * | 1990-09-27 | 1992-08-18 | Merck & Co Inc | Fibrinogen receptor antagonists and pharmaceutical compositions containing them |
NZ239846A (en) * | 1990-09-27 | 1994-11-25 | Merck & Co Inc | Sulphonamide derivatives and pharmaceutical compositions thereof |
IL99527A (en) * | 1990-09-28 | 1997-08-14 | Lilly Co Eli | Tripeptide antithrombotic agents |
GB9024129D0 (en) * | 1990-11-06 | 1990-12-19 | Thrombosis Research Trust | Inhibitors and substrates of thrombin |
AU8868991A (en) * | 1990-11-15 | 1992-06-11 | Pentapharm Ag | Meta-substituted phenyl alanine derivatives |
DE4115468A1 (de) * | 1991-05-11 | 1992-11-12 | Behringwerke Ag | Amidinophenylalaninderivate, verfahren zu deren herstellung, deren verwendung und diese enthaltende mittel als antikoagulantien |
SE9102462D0 (sv) * | 1991-08-28 | 1991-08-28 | Astra Ab | New isosteric peptides |
CZ333492A3 (en) * | 1991-11-12 | 1993-09-15 | Lilly Co Eli | Dipeptide of l-azetidine-2-carboxylic acids and l-argininaldehyde, process of its preparation and pharmaceutical preparation in which said dipeptide is comprised |
SE9103612D0 (sv) * | 1991-12-04 | 1991-12-04 | Astra Ab | New peptide derivatives |
US5583146A (en) * | 1992-12-02 | 1996-12-10 | Bristol-Myers Squibb Company | Heterocyclic thrombin inhibitors |
SE9301916D0 (sv) * | 1993-06-03 | 1993-06-03 | Ab Astra | New peptides derivatives |
US5780631A (en) * | 1993-06-03 | 1998-07-14 | Astra Aktiebolag | Starting materials in the synthesis of thrombin and kininogenase inhibitors |
CA2140598C (en) * | 1994-01-27 | 2010-03-09 | Masahiro Ohshima | Prolineamide derivatives |
US5707966A (en) * | 1994-03-04 | 1998-01-13 | Eli Lilly And Company | Antithrombotic agents |
US5726159A (en) * | 1994-03-04 | 1998-03-10 | Eli Lilly And Company | Antithrombotic agents |
US5705487A (en) * | 1994-03-04 | 1998-01-06 | Eli Lilly And Company | Antithrombotic agents |
SE504185C2 (sv) * | 1994-11-08 | 1996-12-02 | Astra Ab | Lagringsstabil vattenlösning för infusion av trombininhibitorer |
SE9404196D0 (sv) * | 1994-12-02 | 1994-12-02 | Astra Ab | New antithrombotic formulation |
US5710130A (en) * | 1995-02-27 | 1998-01-20 | Eli Lilly And Company | Antithrombotic agents |
AR005245A1 (es) * | 1995-12-21 | 1999-04-28 | Astrazeneca Ab | Prodrogas de inhibidores de trombina, una formulación farmaceutica que las comprende, el uso de dichas prodrogas para la manufactura de un medicamento y un procedimiento para su preparacion |
-
1993
- 1993-06-03 SE SE19939301916A patent/SE9301916D0/xx unknown
-
1994
- 1994-02-06 UA UA95115078A patent/UA65518C2/uk unknown
- 1994-05-05 TW TW083104085A patent/TW403731B/zh active
- 1994-05-12 IL IL10963494A patent/IL109634A/xx not_active IP Right Cessation
- 1994-05-12 IL IL123996A patent/IL123996A/en not_active IP Right Cessation
- 1994-05-16 IS IS4166A patent/IS1805B/is unknown
- 1994-05-17 HR HR940311A patent/HRP940311B1/xx not_active IP Right Cessation
- 1994-06-01 MX MX9404114A patent/MX9404114A/es not_active IP Right Cessation
- 1994-06-02 RU RU96101161A patent/RU2142469C1/ru not_active IP Right Cessation
- 1994-06-02 NZ NZ267534A patent/NZ267534A/xx not_active IP Right Cessation
- 1994-06-02 CN CN94192799A patent/CN1099425C/zh not_active Expired - Fee Related
- 1994-06-02 DK DK94918636T patent/DK0701568T3/da active
- 1994-06-02 ES ES94918636T patent/ES2128277T3/es not_active Expired - Lifetime
- 1994-06-02 EP EP00121659A patent/EP1067136A1/en not_active Withdrawn
- 1994-06-02 CZ CZ19953020A patent/CZ290104B6/cs not_active IP Right Cessation
- 1994-06-02 SG SG1996006171A patent/SG48013A1/en unknown
- 1994-06-02 AT AT94918636T patent/ATE200783T1/de active
- 1994-06-02 WO PCT/SE1994/000535 patent/WO1994029336A1/en active IP Right Grant
- 1994-06-02 HU HU0103039A patent/HU0103039D0/hu not_active Application Discontinuation
- 1994-06-02 JP JP50166595A patent/JP3205558B2/ja not_active Expired - Fee Related
- 1994-06-02 EG EG32494A patent/EG20671A/xx active
- 1994-06-02 HU HU9503445A patent/HU226825B1/hu not_active IP Right Cessation
- 1994-06-02 PT PT94918636T patent/PT701568E/pt unknown
- 1994-06-02 PL PL94311819A patent/PL181968B1/pl not_active IP Right Cessation
- 1994-06-02 KR KR1019950705448A patent/KR100339456B1/ko not_active IP Right Cessation
- 1994-06-02 MY MYPI94001423A patent/MY119155A/en unknown
- 1994-06-02 DE DE122004000045C patent/DE122004000045I2/de active Active
- 1994-06-02 DE DE69427150T patent/DE69427150T2/de not_active Expired - Lifetime
- 1994-06-02 EP EP94918636A patent/EP0701568B1/en not_active Expired - Lifetime
- 1994-06-02 SI SI9430365T patent/SI0701568T1/xx unknown
- 1994-06-02 BR BR9406746A patent/BR9406746A/pt not_active Application Discontinuation
- 1994-06-02 SK SK1454-95A patent/SK283150B6/sk not_active IP Right Cessation
- 1994-06-02 DE DE0701568T patent/DE701568T1/de active Pending
- 1994-06-02 CA CA002162900A patent/CA2162900C/en not_active Expired - Fee Related
- 1994-06-03 RS YUP-336/94A patent/RS49576B/sr unknown
- 1994-06-03 LT LTIP1947A patent/LT3768B/lt not_active IP Right Cessation
- 1994-07-03 SA SA94150051A patent/SA94150051B1/ar unknown
- 1994-11-23 EE EE9400456A patent/EE03264B1/xx not_active IP Right Cessation
-
1995
- 1995-06-06 US US08/468,046 patent/US5602253A/en not_active Expired - Lifetime
- 1995-06-06 US US08/470,277 patent/US5723444A/en not_active Expired - Lifetime
- 1995-06-07 US US08/481,811 patent/US5939392A/en not_active Expired - Lifetime
- 1995-11-30 NO NO19954873A patent/NO314406B1/no not_active IP Right Cessation
- 1995-12-04 FI FI955828A patent/FI119812B/fi active IP Right Grant
-
1999
- 1999-11-15 CN CNB991248597A patent/CN1178905C/zh not_active Expired - Fee Related
-
2001
- 2001-03-28 JP JP2001091958A patent/JP2001322974A/ja active Pending
- 2001-03-28 HK HK01102259A patent/HK1031375A1/xx not_active IP Right Cessation
- 2001-05-28 JP JP2001158596A patent/JP2002047264A/ja active Pending
- 2001-07-24 GR GR20010401107T patent/GR3036258T3/el unknown
-
2004
- 2004-12-13 NO NO2004009C patent/NO2004009I1/no unknown
-
2005
- 2005-03-03 NL NL300178C patent/NL300178I2/nl unknown
- 2005-03-25 US US11/090,786 patent/US20050222395A1/en not_active Abandoned
- 2005-05-11 LU LU91173C patent/LU91173I2/fr unknown
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006249098A (ja) * | 1994-01-27 | 2006-09-21 | Mitsubishi Chemicals Corp | プロリンアミド誘導体 |
JP4561696B2 (ja) * | 1994-01-27 | 2010-10-13 | 三菱化学株式会社 | プロリンアミド誘導体 |
JP2006321807A (ja) * | 1997-06-19 | 2006-11-30 | Astrazeneca Ab | 新規なアミジノ誘導体およびトロンビン阻害剤としてのその使用 |
JP2007039472A (ja) * | 1998-09-03 | 2007-02-15 | Astrazeneca Ab | 速放性錠剤 |
JP2002532467A (ja) * | 1998-12-14 | 2002-10-02 | アストラゼネカ アクチボラグ | 新規アミジノ誘導体およびトロンビン阻害剤としてのそれらの使用 |
JP2002543148A (ja) * | 1999-05-03 | 2002-12-17 | アストラゼネカ アクチボラグ | カルボキシペプチダーゼu阻害剤とトロンビン阻害剤とを含有する医薬製剤 |
JP2003503508A (ja) * | 1999-07-02 | 2003-01-28 | アストラゼネカ アクチボラグ | メラガトランの実質的結晶形 |
JP2004512376A (ja) * | 2000-11-06 | 2004-04-22 | アストラゼネカ アクチボラグ | 虚血性障害の処置用医薬品の製造のためのメラガトランの使用 |
JP2007536197A (ja) * | 2003-06-25 | 2007-12-13 | アストラゼネカ アクチボラグ | メラガトランの新規製造法 |
JP2011519845A (ja) * | 2008-04-29 | 2011-07-14 | ヴァンティア リミテッド | アミノピリジン誘導体 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3205558B2 (ja) | 新規ペプチド誘導体 | |
JP3306826B2 (ja) | 新規なペプチド誘導体 | |
US5780631A (en) | Starting materials in the synthesis of thrombin and kininogenase inhibitors | |
US6617320B2 (en) | Amino acid derivatives | |
US6984627B1 (en) | Peptide derivatives | |
WO2004110432A1 (en) | Enalapril-nitroxyderivatives derivatives and related compounds as ace inhibitors for the treatment of cardiovascular diseases | |
AU684086C (en) | New peptide derivatives | |
TW585853B (en) | Novel tripeptide compounds as inhibitors of trypsin-like serine proteases, process for preparation and pharmaceutical composition thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080629 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090629 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100629 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100629 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110629 Year of fee payment: 10 |
|
LAPS | Cancellation because of no payment of annual fees |